US10538556B2 - Anti-HIV peptides - Google Patents
Anti-HIV peptides Download PDFInfo
- Publication number
- US10538556B2 US10538556B2 US15/805,933 US201715805933A US10538556B2 US 10538556 B2 US10538556 B2 US 10538556B2 US 201715805933 A US201715805933 A US 201715805933A US 10538556 B2 US10538556 B2 US 10538556B2
- Authority
- US
- United States
- Prior art keywords
- peptide
- amino acid
- tar
- seq
- hiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 273
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 72
- 230000036436 anti-hiv Effects 0.000 title 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims abstract description 57
- 108010069514 Cyclic Peptides Proteins 0.000 claims description 127
- 102000001189 Cyclic Peptides Human genes 0.000 claims description 127
- 238000007363 ring formation reaction Methods 0.000 claims description 101
- 235000001014 amino acid Nutrition 0.000 claims description 100
- 150000001413 amino acids Chemical group 0.000 claims description 91
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 82
- 238000000034 method Methods 0.000 claims description 71
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 52
- 230000003993 interaction Effects 0.000 claims description 46
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 claims description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 11
- 235000018417 cysteine Nutrition 0.000 claims description 8
- 150000001945 cysteines Chemical class 0.000 claims description 5
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 abstract description 24
- 125000004122 cyclic group Chemical group 0.000 abstract description 15
- 108091027070 Trans-activation response element (TAR) Proteins 0.000 abstract description 3
- 229940024606 amino acid Drugs 0.000 description 90
- -1 RNP amino acids Chemical class 0.000 description 64
- 210000004027 cell Anatomy 0.000 description 63
- 230000027455 binding Effects 0.000 description 53
- 108090000623 proteins and genes Proteins 0.000 description 52
- 150000001875 compounds Chemical class 0.000 description 50
- 229920002477 rna polymer Polymers 0.000 description 49
- 235000018102 proteins Nutrition 0.000 description 37
- 102000004169 proteins and genes Human genes 0.000 description 37
- 238000011282 treatment Methods 0.000 description 34
- 125000006239 protecting group Chemical group 0.000 description 30
- 239000002585 base Substances 0.000 description 27
- 239000011347 resin Substances 0.000 description 27
- 229920005989 resin Polymers 0.000 description 27
- 101710106597 U1 small nuclear ribonucleoprotein A Proteins 0.000 description 26
- 125000005647 linker group Chemical group 0.000 description 21
- 239000013598 vector Substances 0.000 description 21
- 235000009697 arginine Nutrition 0.000 description 19
- 239000013078 crystal Substances 0.000 description 19
- 150000003839 salts Chemical class 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 101710149951 Protein Tat Proteins 0.000 description 18
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 17
- 108020001507 fusion proteins Proteins 0.000 description 17
- 102000037865 fusion proteins Human genes 0.000 description 17
- 238000000111 isothermal titration calorimetry Methods 0.000 description 17
- 239000002253 acid Substances 0.000 description 16
- 210000004899 c-terminal region Anatomy 0.000 description 16
- 238000005859 coupling reaction Methods 0.000 description 16
- 239000003814 drug Substances 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 14
- 208000030507 AIDS Diseases 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 239000004475 Arginine Substances 0.000 description 12
- 208000031886 HIV Infections Diseases 0.000 description 12
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 12
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000003550 marker Substances 0.000 description 12
- 230000003612 virological effect Effects 0.000 description 12
- 208000037357 HIV infectious disease Diseases 0.000 description 11
- 102000002669 Small Ubiquitin-Related Modifier Proteins Human genes 0.000 description 11
- 108010043401 Small Ubiquitin-Related Modifier Proteins Proteins 0.000 description 11
- 241000700605 Viruses Species 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000010168 coupling process Methods 0.000 description 11
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000013518 transcription Methods 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000008878 coupling Effects 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 101100246066 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PUB1 gene Proteins 0.000 description 9
- 125000003277 amino group Chemical group 0.000 description 9
- 238000000329 molecular dynamics simulation Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 101150050176 rnp1 gene Proteins 0.000 description 9
- 231100000419 toxicity Toxicity 0.000 description 9
- 230000001988 toxicity Effects 0.000 description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 150000001408 amides Chemical class 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 125000000524 functional group Chemical group 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 150000001484 arginines Chemical class 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 210000001163 endosome Anatomy 0.000 description 6
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- ZQBFAOFFOQMSGJ-UHFFFAOYSA-N hexafluorobenzene Chemical compound FC1=C(F)C(F)=C(F)C(F)=C1F ZQBFAOFFOQMSGJ-UHFFFAOYSA-N 0.000 description 6
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 102220595571 Major vault protein_R52A_mutation Human genes 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 102220521752 Ribosome biogenesis protein NSA2 homolog_R47A_mutation Human genes 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 108091006047 fluorescent proteins Proteins 0.000 description 5
- 102000034287 fluorescent proteins Human genes 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 102220598631 5-hydroxytryptamine receptor 1E_R49A_mutation Human genes 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 101710205625 Capsid protein p24 Proteins 0.000 description 4
- 150000008574 D-amino acids Chemical class 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical group NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- YPIGGYHFMKJNKV-UHFFFAOYSA-N N-ethylglycine Chemical compound CC[NH2+]CC([O-])=O YPIGGYHFMKJNKV-UHFFFAOYSA-N 0.000 description 4
- 108010065338 N-ethylglycine Proteins 0.000 description 4
- KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 4
- 101710177166 Phosphoprotein Proteins 0.000 description 4
- 230000004570 RNA-binding Effects 0.000 description 4
- 101710149279 Small delta antigen Proteins 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 238000006664 bond formation reaction Methods 0.000 description 4
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 210000000172 cytosol Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 235000019833 protease Nutrition 0.000 description 4
- 101150106848 rnp-2 gene Proteins 0.000 description 4
- 108010004034 stable plasma protein solution Proteins 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000001757 thermogravimetry curve Methods 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000024188 Andala Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 3
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 150000008575 L-amino acids Chemical class 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 3
- 235000008206 alpha-amino acids Nutrition 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 238000013480 data collection Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 230000000149 penetrating effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000001566 pro-viral effect Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 238000002818 protein evolution Methods 0.000 description 3
- 108010054624 red fluorescent protein Proteins 0.000 description 3
- 238000006798 ring closing metathesis reaction Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- 229940063675 spermine Drugs 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 231100001274 therapeutic index Toxicity 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 description 2
- 101710097567 12 kDa protein Proteins 0.000 description 2
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 2
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
- RDFMDVXONNIGBC-UHFFFAOYSA-N 2-aminoheptanoic acid Chemical compound CCCCCC(N)C(O)=O RDFMDVXONNIGBC-UHFFFAOYSA-N 0.000 description 2
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 2
- MEYMBLGOKYDGLZ-UHFFFAOYSA-N 7-aminomethyl-7-deazaguanine Chemical compound N1=C(N)NC(=O)C2=C1NC=C2CN MEYMBLGOKYDGLZ-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 101710201279 Biotin carboxyl carrier protein Proteins 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 102220588724 C2 domain-containing protein 5_P51A_mutation Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102220560397 GA-binding protein subunit beta-1_Q48E_mutation Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- JUQLUIFNNFIIKC-YFKPBYRVSA-N L-2-aminopimelic acid Chemical compound OC(=O)[C@@H](N)CCCCC(O)=O JUQLUIFNNFIIKC-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-Isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 2
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 2
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101710164418 Movement protein TGB2 Proteins 0.000 description 2
- SCIFESDRCALIIM-UHFFFAOYSA-N N-Me-Phenylalanine Natural products CNC(C(O)=O)CC1=CC=CC=C1 SCIFESDRCALIIM-UHFFFAOYSA-N 0.000 description 2
- OLNLSTNFRUFTLM-UHFFFAOYSA-N N-ethylasparagine Chemical compound CCNC(C(O)=O)CC(N)=O OLNLSTNFRUFTLM-UHFFFAOYSA-N 0.000 description 2
- PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical group CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 2
- SCIFESDRCALIIM-VIFPVBQESA-N N-methyl-L-phenylalanine Chemical compound C[NH2+][C@H](C([O-])=O)CC1=CC=CC=C1 SCIFESDRCALIIM-VIFPVBQESA-N 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- 102220567109 Ornithine decarboxylase antizyme 1_R47Q_mutation Human genes 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 108010077895 Sarcosine Proteins 0.000 description 2
- 102220471540 Single-stranded DNA cytosine deaminase_Y31H_mutation Human genes 0.000 description 2
- 102220512015 Synaptotagmin-7_Q54A_mutation Human genes 0.000 description 2
- 108700005078 Synthetic Genes Proteins 0.000 description 2
- 102100036407 Thioredoxin Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000005076 adamantyloxycarbonyl group Chemical group C12(CC3CC(CC(C1)C3)C2)OC(=O)* 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 230000007253 cellular alteration Effects 0.000 description 2
- 102000021178 chitin binding proteins Human genes 0.000 description 2
- 108091011157 chitin binding proteins Proteins 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 108010021843 fluorescent protein 583 Proteins 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000011654 magnesium acetate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000006140 methanolysis reaction Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000002687 nonaqueous vehicle Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 238000011170 pharmaceutical development Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 238000000275 quality assurance Methods 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 102200145452 rs121908580 Human genes 0.000 description 2
- 102220007445 rs202088921 Human genes 0.000 description 2
- 102220185599 rs781412138 Human genes 0.000 description 2
- 229910052594 sapphire Inorganic materials 0.000 description 2
- 239000010980 sapphire Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010583 slow cooling Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000005469 synchrotron radiation Effects 0.000 description 2
- 238000010381 tandem affinity purification Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 108060008226 thioredoxin Proteins 0.000 description 2
- 229940094937 thioredoxin Drugs 0.000 description 2
- YSMODUONRAFBET-WHFBIAKZSA-N threo-5-hydroxy-L-lysine Chemical compound NC[C@@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-WHFBIAKZSA-N 0.000 description 2
- 230000036964 tight binding Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- GIDNRVZDUMNLRK-GFCCVEGCSA-N (2S)-2-amino-2,3-dimethyl-3-phenylbutanoic acid Chemical compound CC([C@](N)(C(=O)O)C)(C1=CC=CC=C1)C GIDNRVZDUMNLRK-GFCCVEGCSA-N 0.000 description 1
- BTLHODXEDLCLAD-VKHMYHEASA-N (2s)-2-(carboxymethylamino)butanedioic acid Chemical compound OC(=O)CN[C@H](C(O)=O)CC(O)=O BTLHODXEDLCLAD-VKHMYHEASA-N 0.000 description 1
- FPDYKABXINADKS-LURJTMIESA-N (2s)-2-(methylazaniumyl)hexanoate Chemical compound CCCC[C@H](NC)C(O)=O FPDYKABXINADKS-LURJTMIESA-N 0.000 description 1
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 description 1
- CCQGGCWKGAMHGT-KKMMWDRVSA-N (2s)-2-[(4-aminocyclohexyl)amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC1CCC(N)CC1 CCQGGCWKGAMHGT-KKMMWDRVSA-N 0.000 description 1
- VDEMEKSASUGYHM-AXDSSHIGSA-N (2s)-3-phenylpyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@H]1NCCC1C1=CC=CC=C1 VDEMEKSASUGYHM-AXDSSHIGSA-N 0.000 description 1
- UHPQFNXOFFPHJW-UHFFFAOYSA-N (4-methylphenyl)-phenylmethanamine Chemical compound C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 UHPQFNXOFFPHJW-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- VHYBUUMUUNCHCK-UHFFFAOYSA-N 2,4,6-tribromo-1,3,5-triazine Chemical compound BrC1=NC(Br)=NC(Br)=N1 VHYBUUMUUNCHCK-UHFFFAOYSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- OMGHIGVFLOPEHJ-UHFFFAOYSA-N 2,5-dihydro-1h-pyrrol-1-ium-2-carboxylate Chemical compound OC(=O)C1NCC=C1 OMGHIGVFLOPEHJ-UHFFFAOYSA-N 0.000 description 1
- YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 description 1
- AENZGWONVTXLRC-UHFFFAOYSA-N 2-(2,5-dioxopyrrol-1-yl)benzoic acid Chemical class OC(=O)C1=CC=CC=C1N1C(=O)C=CC1=O AENZGWONVTXLRC-UHFFFAOYSA-N 0.000 description 1
- MDNSLPICAWKNAG-UHFFFAOYSA-N 2-(2,5-dioxopyrrol-1-yl)propanoic acid Chemical class OC(=O)C(C)N1C(=O)C=CC1=O MDNSLPICAWKNAG-UHFFFAOYSA-N 0.000 description 1
- VYCNOBNEBXGHKT-UHFFFAOYSA-N 2-(2-methylhydrazinyl)acetic acid Chemical compound CNNCC(O)=O VYCNOBNEBXGHKT-UHFFFAOYSA-N 0.000 description 1
- CLTMYNWFSDZKKI-UHFFFAOYSA-N 2-(aminomethyl)benzoic acid Chemical compound NCC1=CC=CC=C1C(O)=O CLTMYNWFSDZKKI-UHFFFAOYSA-N 0.000 description 1
- CQJAWZCYNRBZDL-UHFFFAOYSA-N 2-(methylazaniumyl)butanoate Chemical compound CCC(NC)C(O)=O CQJAWZCYNRBZDL-UHFFFAOYSA-N 0.000 description 1
- UWCBNAVPISMFJZ-GFCCVEGCSA-N 2-[2-[(2r)-3-(tert-butylamino)-2-hydroxypropoxy]phenoxy]-n-methylacetamide Chemical compound CNC(=O)COC1=CC=CC=C1OC[C@H](O)CNC(C)(C)C UWCBNAVPISMFJZ-GFCCVEGCSA-N 0.000 description 1
- GBUGXAULUBTJFM-UHFFFAOYSA-N 2-[bis(methylamino)amino]acetic acid Chemical compound CNN(NC)CC(O)=O GBUGXAULUBTJFM-UHFFFAOYSA-N 0.000 description 1
- AWKHTMQQGCBOPF-UHFFFAOYSA-N 2-amino-1,7-dihydropurin-6-one guanidine Chemical compound NC(=N)N.N1C(N)=NC=2N=CNC2C1=O AWKHTMQQGCBOPF-UHFFFAOYSA-N 0.000 description 1
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- GSWYUZQBLVUEPH-UHFFFAOYSA-N 3-(azaniumylmethyl)benzoate Chemical compound NCC1=CC=CC(C(O)=O)=C1 GSWYUZQBLVUEPH-UHFFFAOYSA-N 0.000 description 1
- KHABBYNLBYZCKP-UHFFFAOYSA-N 4-aminopiperidin-1-ium-4-carboxylate Chemical compound OC(=O)C1(N)CCNCC1 KHABBYNLBYZCKP-UHFFFAOYSA-N 0.000 description 1
- 125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- HCXJFMDOHDNDCC-UHFFFAOYSA-N 5-$l^{1}-oxidanyl-3,4-dihydropyrrol-2-one Chemical class O=C1CCC(=O)[N]1 HCXJFMDOHDNDCC-UHFFFAOYSA-N 0.000 description 1
- HFKRAQJDTVSWNX-UHFFFAOYSA-N 5-amino-2-benzylpentanoic acid Chemical compound NCCCC(C(O)=O)CC1=CC=CC=C1 HFKRAQJDTVSWNX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108091005950 Azurite Proteins 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- 241000713704 Bovine immunodeficiency virus Species 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102220584310 Cellular tumor antigen p53_A84G_mutation Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091005944 Cerulean Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000579895 Chlorostilbon Species 0.000 description 1
- 108091005960 Citrine Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108091005943 CyPet Proteins 0.000 description 1
- 108010068106 Cyclin T Proteins 0.000 description 1
- 102000020149 Cyclin-T1 Human genes 0.000 description 1
- 102100024109 Cyclin-T1 Human genes 0.000 description 1
- 108091016115 Cyclin-T1 Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108091005941 EBFP Proteins 0.000 description 1
- 108091005947 EBFP2 Proteins 0.000 description 1
- 108091005942 ECFP Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 229940124602 FDA-approved drug Drugs 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000617779 Homo sapiens U1 small nuclear ribonucleoprotein A Proteins 0.000 description 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 125000000899 L-alpha-glutamyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101150018665 MAPK3 gene Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- NSTPXGARCQOSAU-VIFPVBQESA-N N-formyl-L-phenylalanine Chemical compound O=CN[C@H](C(=O)O)CC1=CC=CC=C1 NSTPXGARCQOSAU-VIFPVBQESA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 108010088535 Pep-1 peptide Proteins 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 108010052090 Renilla Luciferases Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 108010076818 TEV protease Proteins 0.000 description 1
- 101710192266 Tegument protein VP22 Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 241000545067 Venus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- UXZMLECYBHANRH-UHFFFAOYSA-K [B+3].[O-]C(=O)C(F)(F)F.[O-]C(=O)C(F)(F)F.[O-]C(=O)C(F)(F)F Chemical compound [B+3].[O-]C(=O)C(F)(F)F.[O-]C(=O)C(F)(F)F.[O-]C(=O)C(F)(F)F UXZMLECYBHANRH-UHFFFAOYSA-K 0.000 description 1
- GELXFVQAWNTGPQ-UHFFFAOYSA-N [N].C1=CNC=N1 Chemical compound [N].C1=CNC=N1 GELXFVQAWNTGPQ-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 231100000569 acute exposure Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005910 alkyl carbonate group Chemical group 0.000 description 1
- 125000005431 alkyl carboxamide group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- QCTBMLYLENLHLA-UHFFFAOYSA-N aminomethylbenzoic acid Chemical compound NCC1=CC=C(C(O)=O)C=C1 QCTBMLYLENLHLA-UHFFFAOYSA-N 0.000 description 1
- 238000005915 ammonolysis reaction Methods 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 108091005948 blue fluorescent proteins Proteins 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- YSMHTFWPDRJCMN-UHFFFAOYSA-N butan-2-yl carbonochloridate Chemical compound CCC(C)OC(Cl)=O YSMHTFWPDRJCMN-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000004803 chlorobenzyl group Chemical group 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000011035 citrine Substances 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 108010082025 cyan fluorescent protein Proteins 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000010976 emerald Substances 0.000 description 1
- 229910052876 emerald Inorganic materials 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000000021 endosomolytic effect Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-M fusidate Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-M 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000007440 host cell apoptosis Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 239000013264 metal-organic assembly Substances 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 210000003365 myofibril Anatomy 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- UPXAZUFKXWLNMF-UHFFFAOYSA-N n'-propan-2-ylmethanediimine Chemical compound CC(C)N=C=N UPXAZUFKXWLNMF-UHFFFAOYSA-N 0.000 description 1
- 108700043045 nanoluc Proteins 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 206010073131 oligoastrocytoma Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000004810 partition chromatography Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 150000003858 primary carboxamides Chemical class 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000002976 reverse transcriptase assay Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 102220002280 rs121908541 Human genes 0.000 description 1
- 102200029469 rs63750123 Human genes 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical compound CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 description 1
- NPDBDJFLKKQMCM-UHFFFAOYSA-N tert-butylglycine Chemical compound CC(C)(C)C(N)C(O)=O NPDBDJFLKKQMCM-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000004149 thio group Chemical group *S* 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- GWBUNZLLLLDXMD-UHFFFAOYSA-H tricopper;dicarbonate;dihydroxide Chemical compound [OH-].[OH-].[Cu+2].[Cu+2].[Cu+2].[O-]C([O-])=O.[O-]C([O-])=O GWBUNZLLLLDXMD-UHFFFAOYSA-H 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- HIV-1 Trans-Activation Response element HIV-1 TAR
- HIV/AIDS afflicts nearly 37 million people worldwide. At present there is no cure or vaccine.
- New antivirals must be developed to combat drug resistance, while addressing the needs of an aging population requiring decades of therapy compliance.
- Existing FDA-approved drugs target many facets of the viral life cycle. To improve long-term therapeutic outcome, modulation of new targets—especially those resistant to mutation—is needed.
- the HIV-1 Trans-Activation Responsive element is highly resistant to mutation and plays important roles in facilitating proviral transcription and blocking apoptosis of the infected host cell.
- TAR has been refractory to the discovery of small-molecules or peptides with sufficient affinity and selectivity to warrant pharmaceutical development.
- Crawford et al. described 70 different proteins, referred to as TAR binding proteins (TBPs), that specifically recognize TAR through combined interactions of the N- and C-terminal helix present in each TBP (Crawford et al. ACS Chem Biol, 2016, 11(8): 2206-2215).
- TBPs TAR binding proteins
- the present disclosure encompasses an isolated peptide consisting of an amino acid sequence of SEQ ID NO: 2, or a derivative or a conjugate thereof, wherein the isolated peptide, derivative, or conjugate specifically binds to HIV-1 trans-activation responsive RNA.
- the peptide can be linear or cyclic.
- the peptide can be cyclized by head-to-tail cyclization, side chain-to-tail cyclization, head-to-side chain cyclization, or side chain-to-side chain cyclization.
- the present disclosure also encompasses pharmaceutical compositions comprising said peptides.
- the present disclosure encompasses an isolated peptide consisting of an amino acid sequence of SEQ ID NO: 3, or a derivative or a conjugate thereof, wherein the isolated peptide, derivative, or conjugate specifically binds to HIV-1 trans-activation responsive RNA.
- the peptide can be linear or cyclic.
- the peptide can be cyclized by head-to-tail cyclization, side chain-to-tail cyclization, head-to-side chain cyclization, or side chain-to-side chain cyclization.
- the present disclosure also encompasses pharmaceutical compositions comprising said peptide.
- the present disclosure encompasses an isolated peptide consisting of an amino acid sequence of SEQ ID NO: 4, or a derivative or a conjugate thereof, wherein the isolated peptide, derivative, or conjugate specifically binds to HIV-1 trans-activation responsive RNA.
- the peptide can be linear or cyclic.
- the peptide can be cyclized by head-to-tail cyclization, side chain-to-tail cyclization, head-to-side chain cyclization, or side chain-to-side chain cyclization.
- the present disclosure also encompasses pharmaceutical compositions comprising said peptide.
- the present disclosure encompasses an isolated peptide consisting of residues 4 to 16 of an amino acid sequence selected from the group SEQ ID NO: 8 to SEQ ID NO: 24, or a derivative or a conjugate thereof, wherein the isolated peptide, derivative, or conjugate specifically binds to HIV-1 trans-activation responsive RNA.
- the peptide can be linear or cyclic.
- the peptide can be cyclized by head-to-tail cyclization, side chain-to-tail cyclization, head-to-side chain cyclization, or side chain-to-side chain cyclization.
- the present disclosure also encompasses pharmaceutical compositions comprising said peptide.
- the present disclosure encompasses an isolated peptide consisting of an amino acid sequence of SEQ ID NO: 5, or a derivative or a conjugate thereof, wherein the isolated peptide, derivative, or conjugate specifically binds to HIV-1 trans-activation responsive RNA.
- the peptide can be linear or cyclic.
- the peptide can be cyclized by head-to-tail cyclization, side chain-to-tail cyclization, head-to-side chain cyclization, or side chain-to-side chain cyclization.
- the present disclosure also encompasses pharmaceutical compositions comprising said peptide.
- the present disclosure encompasses an isolated peptide consisting of an amino acid sequence of SEQ ID NO: 6, or a derivative or a conjugate thereof, wherein the isolated peptide, derivative, or conjugate specifically binds to HIV-1 trans-activation responsive RNA.
- the peptide can be linear or cyclic.
- the peptide can be cyclized by head-to-tail cyclization, side chain-to-tail cyclization, head-to-side chain cyclization, or side chain-to-side chain cyclization.
- the present disclosure also encompasses pharmaceutical compositions comprising said peptide.
- the present disclosure encompasses an isolated peptide consisting of an amino acid sequence of SEQ ID NO: 7, or a derivative or a conjugate thereof, wherein the isolated peptide, derivative, or conjugate specifically binds to HIV-1 trans-activation responsive RNA.
- the peptide can be linear or cyclic.
- the peptide can be cyclized by head-to-tail cyclization, side chain-to-tail cyclization, head-to-side chain cyclization, or side chain-to-side chain cyclization.
- the present disclosure also encompasses pharmaceutical compositions comprising said peptide.
- the present disclosure encompasses an isolated peptide selected from the group SEQ ID NO: 8 to SEQ ID NO: 24, or a derivative or a conjugate thereof, wherein the isolated peptide, derivative, or conjugate specifically binds to HIV-1 trans-activation responsive RNA.
- the peptide can be linear or cyclic.
- the peptide can be cyclized by head-to-tail cyclization, side chain-to-tail cyclization, head-to-side chain cyclization, or side chain-to-side chain cyclization.
- the present disclosure also encompasses pharmaceutical compositions comprising said peptide.
- the present disclosure encompasses a cyclic peptide comprising an amino acid sequence of SEQ ID NO: 2, or a derivative or a conjugate thereof.
- the peptide can be cyclized by head-to-tail cyclization, side chain-to-tail cyclization, head-to-side chain cyclization, or side chain-to-side chain cyclization.
- the present disclosure also encompasses pharmaceutical compositions comprising said peptide.
- the present disclosure encompasses a cyclic peptide comprising an amino acid sequence of SEQ ID NO: 3, or a derivative or a conjugate thereof.
- the peptide can be cyclized by head-to-tail cyclization, side chain-to-tail cyclization, head-to-side chain cyclization, or side chain-to-side chain cyclization.
- the present disclosure also encompasses pharmaceutical compositions comprising said peptide.
- the present disclosure encompasses a cyclic peptide comprising an amino acid sequence of SEQ ID NO: 4, or a derivative or a conjugate thereof.
- the peptide can be cyclized by head-to-tail cyclization, side chain-to-tail cyclization, head-to-side chain cyclization, or side chain-to-side chain cyclization.
- the present disclosure also encompasses pharmaceutical compositions comprising said peptide.
- the present disclosure encompasses a cyclic peptide comprising residues 4 to 16 of an amino acid selected from the group SEQ ID NO: 8 to SEQ ID NO: 24, or a derivative or a conjugate thereof.
- the peptide can be cyclized by head-to-tail cyclization, side chain-to-tail cyclization, head-to-side chain cyclization, or side chain-to-side chain cyclization.
- the present disclosure also encompasses pharmaceutical compositions comprising said peptide.
- the present disclosure encompasses a cyclic peptide comprising an amino acid sequence of SEQ ID NO: 5, or a derivative or a conjugate thereof.
- the peptide can be cyclized by head-to-tail cyclization, side chain-to-tail cyclization, head-to-side chain cyclization, or side chain-to-side chain cyclization.
- the present disclosure also encompasses pharmaceutical compositions comprising said peptide.
- the present disclosure encompasses a cyclic peptide comprising an amino acid sequence of SEQ ID NO: 6, or a derivative or a conjugate thereof.
- the peptide can be cyclized by head-to-tail cyclization, side chain-to-tail cyclization, head-to-side chain cyclization, or side chain-to-side chain cyclization.
- the present disclosure also encompasses pharmaceutical compositions comprising said peptide.
- the present disclosure encompasses a cyclic peptide comprising an amino acid sequence of SEQ ID NO: 7, or a derivative or a conjugate thereof.
- the peptide can be cyclized by head-to-tail cyclization, side chain-to-tail cyclization, head-to-side chain cyclization, or side chain-to-side chain cyclization.
- the present disclosure also encompasses pharmaceutical compositions comprising said peptide.
- the present disclosure encompasses a cyclic peptide comprising an amino acid sequence selected from the group SEQ ID NO: 8 to SEQ ID NO: 24, or a derivative or a conjugate thereof.
- the peptide can be cyclized by head-to-tail cyclization, side chain-to-tail cyclization, head-to-side chain cyclization, or side chain-to-side chain cyclization.
- the present disclosure also encompasses pharmaceutical compositions comprising said peptide.
- the present disclosure encompasses a method of inhibiting the interaction between HIV Tat and HIV TAR, the method comprising contacting an HIV infected cell with a linear or cyclic peptide disclosed herein.
- the present disclosure encompasses a method of reducing HIV proliferation, the method comprising contacting an HIV infected cell with a linear or cyclic peptide disclosed herein.
- the present disclosure encompasses a method for treating or preventing an HIV infection, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of a linear or cyclic peptide disclosed herein.
- the present disclosure encompasses a method for treating or preventing a disease or disorder involving HIV, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of a linear or cyclic peptide disclosed herein.
- FIG. 1A-B depict ⁇ 2- ⁇ 3 loop interactions between TBP6.7 and HIV-1 TAR RNA based on the crystal structure.
- A Schematic of the global protein-RNA interactions as thick dashed lines (black). Asterisks (*) indicate evolved residues. Red nucleotides are directly engaged.
- B ⁇ 2- ⁇ 3 loop close-up and global structure (inset) depicting amino acid interactions to the TAR (UCU) bulge and upper stem; thin lines (blue) show hydrogen (H) bonding base pairs.
- FIG. 2 depicts the ⁇ 2- ⁇ 3 hairpin from TBP6.7.
- Peptides of the present disclosure preserve the ⁇ -core, as well as amino acids and H-bond interactions that preserve the loop conformation.
- FIG. 3A-C depict TBP6.7-TAR electron density and comparison of RNA binding.
- A 2mF o -DF c electron density at 1.0 ⁇ for the refined TBP6.7-TAR complex at 1.8 ⁇ resolution.
- B U1A depicting single-stranded RNA recognition by RNP2 (red) and RNP1 (orange) amino acids that are conserved among RRMs.
- C TBP recognizes the upper duplex stem of TAR and does not make full use of RNP amino acids. RNA termini were truncated for clarity.
- FIG. 4A-F depict the TBP evolution screen.
- A Yeast display platform to identify U1A-derived proteins that bind TAR.
- B Consensus sequences of the ⁇ 2- ⁇ 3 loop in 70 clones that were sequenced after six rounds of yeast display screening.
- C ELISA data depicting binding between evolved proteins and TAR.
- D SPR data showing potent and selective recognition between TBP6.6 or TBP6.7 and TAR, but not U1hpII (the starting protein's native target). As expected, U1A does not bind TAR, but tightly binds U1hpII.
- E Sequences of TAR mutants used to elucidate TBP6.6 and TBP 6.7 binding selectivity.
- F ELISA data showing relative affinities between TBP6.6 or TBP6.7.
- FIG. 5 shows representative ITC for TBP6.7-TAR at 37° C. in 0.05 M NaCl, 0.05 M KCl, 2 mM MgCl2, 2 mM ⁇ -mercaptoethanol at pH 7.5.
- FIG. 6A-B depicts SUMO-(GGS) 3 - ⁇ 2- ⁇ 3 and graphs of ELISA data.
- A Diagram of the SUMO-(GGS) 3 - ⁇ 2- ⁇ 3 hairpin loop of TBP6.7 fused to SUMO.
- B ELISA data: SUMO does not bind TAR, U1hpII, or BIV; SUMO-(GGS) 3 - ⁇ 2- ⁇ 3 retains affinity for TAR but does not bind U1hpII or BIV; U1A control binds U1hpII, but not TAR or BIV TAR.
- FIG. 7 depicts a scheme for the synthesis of cyclic peptides via double thiol S N Ar reaction on hexafluorobenzene.
- FIG. 8 depicts the relationship between SEQ ID NO: 1 to 24.
- the present disclosure encompasses the discovery of the critical amino acids in the N-terminus of TBPs that provide specificity for HIV-1 TAR, as well as the discovery of a minimal ⁇ -hairpin that retains TAR affinity and inhibits HIV transcription.
- the peptides, compositions comprising said peptides, and uses thereof are discussed in further detail below.
- HIV refers to a human immunodeficiency virus, and is not limiting in regards to a particular HIV genotype or subtype. Accordingly, the term “HIV” encompasses the two major types, HIV-1 and HIV-2.
- treating refers to both therapeutic treatment and prophylactic or preventative measures.
- Those in need of treatment include those already with the disorder as well as those prone to having the disorder or diagnosed with the disorder or those in which the disorder is to be prevented.
- Consecutive treatment or administration refers to treatment on at least a daily basis without interruption in treatment by one or more days.
- Intermittent treatment or administration, or treatment or administration in an intermittent fashion refers to treatment that is not consecutive, but rather cyclic in nature.
- the treatment regime herein can be either consecutive or intermittent.
- Subjects for whom the preventive measures are appropriate include those with one or more known risk factors for the disorder (e.g., HIV infection or acquired immune deficiency syndrome (AIDS).
- AIDS acquired immune deficiency syndrome
- the term “effective amount” refers to an amount of peptide effective to treat a disease or disorder in a mammal.
- the effective amount of a peptide may: inhibit (i.e., slow to some extent and preferably stop) viral replication; inhibit (i.e., slow to some extent and preferably stop) HIV infection of uninfected cells; reduce the number of HIV infected cells; and/or relieve to some extent one or more of the symptoms associated with the disorder.
- efficacy in vivo can, for example, be measured by a decrease in viral load (i.e., any reduction in plasma HIV ribonucleic acid (RNA) level, though preferably below the level of detection of sensitive HIV-RNA assay), reduced AIDS morbidity, reduced AIDS mortality, an increase in the subject's CD4 + cell count, etc.
- viral load i.e., any reduction in plasma HIV ribonucleic acid (RNA) level, though preferably below the level of detection of sensitive HIV-RNA assay
- RNA ribonucleic acid
- “individual” or “subject” means a mammal, particularly a non-human primate, e.g., apes and monkeys, and most particularly a human.
- pharmaceutical formulation refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.
- a “pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, which is nontoxic to a subject.
- a pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.
- amino acid within the scope of the present invention is used in its broadest sense.
- the term includes L-amino acids and D-amino acids, natural protein occurring amino acids and natural non-protein amino acids, as well as chemically-modified amino acids such as amino acid analogs, and chemically-synthesized compounds having properties known in the art to be characteristic of an amino acid.
- analogs or mimetics of phenylalanine or proline which allow the same conformational restriction of the peptides compounds as natural Phe or Pro, are included within the definition of amino acid.
- Such analogs and mimetics are referred to herein as “functional equivalents” of an amino acid.
- Commonly-encountered amino acids that are not encoded by the genetic code include, for example, those described in WO 90/01940, as well as, for example, 2-amino adipic acid (Aad) for Glu and Asp; 2-aminopimelic acid (Apm) for Glu and Asp; 2-aminobutyric (Abu) acid for Met, Leu, and other aliphatic amino acids; 2-aminoheptanoic acid (Ahe) for Met, Leu, and other aliphatic amino acids; 2-aminoisobutyric acid (Aib) for Gly; cyclohexylalanine (Cha) for Val, Leu and Ile; homoarginine (Har) for Arg and Lys; 2,3-diaminopropionic acid (Dpr) for Lys, Arg, and His; N-ethylglycine (EtGly) for Gly, Pro, and Ala; N-ethylglycine (EtG
- Modified or unusual amino acids which can be used to practice the invention also include D-amino acids, a N-Cbz-protected amino acid, 2,4-diaminobutyric acid, N-methylaminobutyric acid, naphthylalanine, phenylglycine, beta-phenylproline, tert-leucine, 4-aminocyclohexylalanine, N-methyl-norleucine, 3,4-dehydroproline, N,N-dimethylaminoglycine, N-methylaminoglycine, 4-aminopiperidine-4-carboxylic acid, 6-aminocaproic acid, trans-4-(aminomethyl)-cyclohexanecarboxylic acid, 2-, 3-, and 4-(aminomethyl)-benzoic acid, 1-aminocyclopentanocarboxylic acid, 1-aminocyclopropanecarboxylic acid, and 2-benzyl-5-aminopentanoi
- “Peptides” are defined herein as organic compounds comprising a chain of two or more amino acids covalently joined by peptide bonds.
- the term “peptide” includes polypeptides.
- peptides of the present disclosure have about 7 to about 70 amino acids, more preferably about 10 to about 30 amino acids, and most preferably about 13 to about 20 amino acids.
- the definition includes linear peptides, cyclic peptides, and peptide derivatives, as well as their salts and optical isomers.
- peptide bond means a covalent amide linkage formed by loss of a molecule of water between the carboxyl group of one amino acid and the amino group of a second amino acid.
- peptide backbone means the chain of atoms of a peptide comprising the carboxamide groups that are the peptide bonds together with the atoms of the amino acids that link the carboxyl and amino groups of the amino acid (usually the ⁇ -carbon of an ⁇ -amino acid).
- side chain means groups that are attached to the peptide backbone, and typically refers to the group attached to the ⁇ -carbon of an ⁇ -amino acid.
- proteinogenic amino acids include: methyl (alanine), hydroxymethyl (serine), benzyl (phenylalanine), mercaptomethyl (cysteine), and carboxymethyl (aspartic acid).
- derivative as applied to compounds comprising a peptide chain means a compound wherein one or more of the amino, hydroxyl, or carboxyl groups in a side chain of a peptide, or the terminal amino or carboxyl groups are modified.
- C-terminal derivative used in reference to a peptide means a peptide where the C-terminal carboxyl group is modified.
- N-terminal derivative used in reference to a peptide means a peptide where the N-terminal amino group is modified.
- one or more of the amino, hydroxyl, or carboxyl groups in a side chain of the peptide, or the terminal amino or carboxyl groups may be modified to a derivative functional group.
- Non-limiting examples of derivative functional groups suitable for amino, hydroxyl, or carboxyl groups in a peptide follow.
- an amino group may be derivatized as an amide (such as an alkyl carboxamide, acetamide), a carbamate (such as an alkyl carbamate, e.g., methyl carbamate or t-butylcarbamate), or a urea.
- a hydroxyl group may be derivatized as an ester (such as an alkanoate, e.g., acetate, propionate, or an arenecarboxylate, e.g., benzoate), a carbamate (such as an alkyl carbamate, e.g.
- a carboxyl group may be derivatized as an ester (such as an alkyl ester, e.g., ethyl ester) or an amide (e.g., primary carboxamide, an N-alkyl secondary carboxamide, or an N,N-dialkylcarboxamide).
- one or more of the amino groups in a side chain or a terminal ⁇ -amino group of a peptide disclosed herein may be modified by an acetyl group, a formyl group, a methyl group, a myristoyl group, a palmitoyl group, a propionyl group, or ubiquitin.
- Other modifications are known in the art.
- derivatives of the peptide may improve an aspect of the peptide (e.g., solubility, susceptibility to peptidases, etc.) without substantially affecting the desired activity of the parent peptide (e.g., specific binding to HIV-1 TAR).
- Preferred embodiments of the invention are those wherein three or fewer of the amino, carboxyl, and hydroxyl groups, and preferably two or fewer, or one or none, are modified.
- the term “derivative” also includes salts of derivatives.
- isolated peptide means a peptide substantially free of contaminants or cell components with which the peptide naturally occurs, or the reagents used in synthesis or the byproducts of synthesis. “Isolated” and “substantially free of contaminants” does not mean that the preparation is technically pure (homogeneous), but it is sufficiently pure to provide the peptide in a form in which it can be used therapeutically.
- cell-penetrating domain refers to a peptide that is capable of crossing cell membranes and of directing the transport of a peptide, protein, or molecule associated with the cell-penetrating domain, from the outside of a cell into the cytoplasm of the cell through the cytoplasmic membrane of the cell.
- conjugated referring to the linking of two peptides means that the two peptides are covalently linked to one another.
- the linking may be accomplished directly, through the formation of an amide bond between the carboxyl group of one peptide and an amino group of the other peptide, or by means of a linking group wherein the linking group has covalent bonds to each of the peptides.
- the linking group may be an amino acid, a peptide, or any group having at least two functional groups and capable of forming covalent bond to each of the two peptide chains.
- directly bound or “directly conjugated”, referring to the joining of two chemical groups, means that the groups are linked by means of a covalent bond (rather than being linked by virtue of each being bound to a linking group).
- a “conjugate,” refers to a compound having two portions covalently linked (conjugated) together, where each of the portions is derived from different proteins.
- the two portions may be linked directly by a single peptide bond or by means of a linking group wherein the linking group has covalent bonds to each of the peptides.
- a “fusion protein” refers to a polypeptide having two portions covalently linked (conjugated) together, where each of the portions is derived from different proteins.
- the two portions may be linked directly by a single peptide bond or through a linker containing one or more amino acid residues. Generally, the two portions and the linker will be in reading frame with each other and are produced using recombinant techniques.
- a fusion protein is an example of a conjugate.
- the present disclosure provides simple ⁇ -hairpin peptides in linear and cyclic form.
- Peptides of the present disclosure preferably bind HIV-1 Trans-Activation Response element (HIV-1 TAR), and more preferably inhibit the HIV-1 Tat-TAR interaction and/or inhibit Tat-dependent long terminal repeat (LTR) transcription.
- HIV-1 TAR HIV-1 Trans-Activation Response element
- LTR Tat-dependent long terminal repeat
- the polynucleotide sequence of HIV-1 TAR is provided as SEQ ID NO: 25.
- Peptides of the present disclosure can be conjugated to one or more additional domains to facilitate expression and/or purification, to direct the peptide to the correct intracellular location, and/or to target to a peptide to an infected cell.
- the present disclosure provides isolated peptides that specifically bind to HIV-1 TAR, as well as derivatives thereof and conjugates thereof.
- derivative is defined above.
- Conjugates are described in further detail in Section II(a).
- Isolated peptides of the present disclosure can be linear or cyclic, and may be comprised of L-amino acids, D-amino acids, natural protein occurring amino acids, natural non-protein amino acids, chemically-modified amino acids, functional equivalents of amino acids, modified or unusual amino acids, or any combination thereof.
- Peptides of the present disclosure, and the derivatives and conjugates thereof, “specifically bind to HIV-1 TAR” when the affinity constant or affinity of interaction (KD) is between about 0.1 pM to about 25 ⁇ M, preferably about 0.1 pM to about 20 ⁇ M, preferably about 0.1 pM to about 1 ⁇ M, more preferably about 0.1 pM to about 100 nM.
- KD affinity constant or affinity of interaction
- an isolated peptide that specifically binds to HIV-1 TAR consists of an amino acid sequence of SEQ ID NO: 2, or is a derivative or conjugate thereof.
- an isolated peptide that specifically binds to HIV-1 TAR consists of an amino acid sequence of SEQ ID NO: 3, or is a derivative or conjugate thereof.
- the amino acid sequence of the isolated peptide may consist of SEQ ID NO: 4, or may be a derivative or conjugate thereof.
- the amino acid sequence of the isolated peptide may consist of residues 4 to 16 of an amino acid sequence selected from the group SEQ ID NO: 8 to SEQ ID NO: 24, or may be a derivative or conjugate thereof.
- the amino acid sequence of the isolated peptide consists of residues 4 to 16 of SEQ ID NO: 15, or is a derivative or conjugate thereof.
- an isolated peptide that specifically binds to HIV-1 TAR comprises of an amino acid sequence of SEQ ID NO: 2 and is 13 to 19 amino acids in length, or is a derivative or conjugate thereof.
- an isolated peptide that specifically binds to HIV-1 TAR comprises an amino acid sequence of SEQ ID NO: 3 and is 13 to 19 amino acids in length, or is a derivative or conjugate thereof.
- the amino acid sequence of the isolated peptide may comprise SEQ ID NO: 4, or may be a derivative or conjugate thereof.
- the amino acid sequence of the isolated peptide may comprise residues 4 to 16 of an amino acid sequence selected from the group SEQ ID NO: 8 to SEQ ID NO: 24, or may be a derivative or conjugate thereof.
- the amino acid sequence of the isolated peptide comprises residues 4 to 16 of SEQ ID NO: 15, or is a derivative or conjugate thereof.
- an isolated peptide that specifically binds to HIV-1 TAR consists of an amino acid sequence of SEQ ID NO: 5, or is a derivative or conjugate thereof.
- an isolated peptide that specifically binds to HIV-1 TAR consists of an amino acid sequence of SEQ ID NO: 6, or is a derivative or conjugate thereof.
- the isolated peptide may consist of an amino acid sequence of SEQ ID NO: 7, or may be a derivative or conjugate thereof.
- the amino acid sequence of the isolated peptide may consist of an amino acid sequence selected from the group SEQ ID NO: 8 to SEQ ID NO: 24, or may be a derivative or conjugate thereof.
- the isolated peptide consists of an amino acid sequence of SEQ ID NO: 15, or is a derivative or conjugate thereof.
- an isolated peptide or derivative thereof that specifically binds to HIV-1 TAR is a cyclic peptide.
- the amino acid sequence of the cyclic peptide consists of SEQ ID NO: 2 or SEQ ID NO: 3, or is a derivative or conjugate thereof.
- the amino acid sequence of the cyclic peptide may consist of SEQ ID NO: 4, or may be a derivative or conjugate thereof.
- the amino acid sequence of the cyclic peptide may consist of residues 4 to 16 of an amino acid sequence selected from the group SEQ ID NO: 8 to SEQ ID NO: 24, or may be a derivative or conjugate thereof.
- the amino acid sequence of the cyclic peptide may consist of residues 4 to 16 of SEQ ID NO: 15, or may be a derivative or conjugate thereof.
- the amino acid sequence of the cyclic peptide consists of SEQ ID NO: 5 or SEQ ID NO: 6, or is a derivative or conjugate thereof.
- the amino acid sequence of the cyclic peptide may consist of SEQ ID NO: 7, or may be a derivative or conjugate thereof.
- the amino acid sequence of the cyclic peptide may consist of an amino acid sequence selected from the group SEQ ID NO: 8 to SEQ ID NO: 2, or may be a derivative or conjugate thereof.
- the amino acid sequence of the cyclic peptide may consist of SEQ ID NO: 15, or may be a derivative or conjugate thereof.
- a derivative may be an N-terminal derivative, a C-terminal derivative, or an N-terminal derivative and a C-terminal derivative.
- the modification improves resistance of the peptide to degradation by peptidases (e.g., N-terminal acetylation, N-terminal methylation, C-terminal amidation, etc.).
- Cyclic peptides of the present disclosure may be comprised of L-amino acids, D-amino acids, natural protein occurring amino acids, natural non-protein amino acids, chemically-modified amino acids, functional equivalents of amino acids, modified or unusual amino acids, or any combination thereof.
- a cyclic peptide comprises an amino acid sequence of SEQ ID NO: 2, or is a derivative or conjugate thereof. In other embodiments, a cyclic peptide comprises an amino acid sequence of SEQ ID NO: 3, or is a derivative or conjugate thereof. In each of the above embodiments, the amino acid sequence of the cyclic peptide may comprise SEQ ID NO: 4, or may be a derivative or conjugate thereof. Alternatively, the amino acid sequence of the cyclic peptide may comprise residues 4 to 16 of an amino acid sequence selected from the group SEQ ID NO: 8 to SEQ ID NO: 24, or may be a derivative or conjugate thereof. In an exemplary embodiment, the amino acid sequence of the cyclic peptide comprises residues 4 to 16 of SEQ ID NO: 15, or is a derivative or conjugate thereof.
- a cyclic peptide comprises an amino acid sequence of SEQ ID NO: 5, or is a derivative or conjugate thereof. In other embodiments, a cyclic peptide comprises an amino acid sequence of SEQ ID NO: 6, or is a derivative or conjugate thereof.
- a cyclic peptide comprising an amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 6, or derivatives or conjugates thereof includes N-terminal truncations of one, two, or three amino acids and/or C-terminal truncations of one, two, or three amino acids.
- the cyclic peptide may comprise an amino acid sequence of SEQ ID NO: 7, or may be a derivative or conjugate thereof.
- the amino acid sequence of the cyclic peptide may comprise an amino acid sequence selected from the group SEQ ID NO: 8 to SEQ ID NO: 24, or may be a derivative or conjugate thereof.
- the cyclic peptide comprises an amino acid sequence of SEQ ID NO: 15, or is a derivative or conjugate thereof.
- the cyclic peptide may be isolated.
- the cyclic peptide in each of the above embodiments may specifically bind to HIV-1 TAR.
- a derivative may be an N-terminal derivative, a C-terminal derivative, or an N-terminal derivative and a C-terminal derivative.
- the modification improves resistance of the peptide to degradation by peptidases (e.g., N-terminal acetylation, N-terminal methylation, C-terminal amidation, etc.).
- the peptide of the present disclosure is a cyclic peptide
- the peptide can be cyclized by head-to-tail cyclization, side chain-to-tail cyclization, head-to-side chain cyclization, or side chain-to-side chain cyclization.
- the ring structure can be formed by any suitable chemistry known in the art and available for ring closure. However, closure via simple disulfide bond formation (e.g., disulfide bond formation between the thiol groups of two cysteine amino acids) is not preferred since the interior of a cell is reducing.
- Non-limiting examples of preferred types of bonds for ring closure include amide, lactone, ether, thioether, thiocarbonyl, etc. Many suitable methods are well-known in the art for preparing cyclized peptides as contemplated herein, and various non-limiting methods are further detailed in Section II (c) and the Examples.
- a cyclic peptide of the present disclosure is formed by conjugating two side chains occupying the same face of the ⁇ -sheet formed by ⁇ -hairpin.
- the side chains of amino acids 1 and 13 of SEQ ID NO: 2 or SEQ ID NO: 3, or SEQ ID NO: 4 are conjugated to form a cyclic peptide.
- the side chains of amino acids 2 and 18 of SEQ ID NO: 5 or SEQ ID NO: 6, or SEQ ID NO: 7 are conjugated to form a cyclic peptide.
- the side chains of amino acids 4 and 16 of SEQ ID NO: 5 or SEQ ID NO: 6, or SEQ ID NO: 7 are conjugated to form a cyclic peptide.
- Amino acids 1 and 13 of SEQ ID NO: 2 or SEQ ID NO: 3, or SEQ ID NO: 4, or amino acids 4 and 16 of any one of SEQ ID NO: 5-24 can be engineered such that side chain-to-side chain cyclization occurs between those positions using methods well-known in the art.
- cysteine residues may be engineered at (a) amino acids 1 and 13 of SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO:4, (b) at amino acids 2 and 18 of SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO:6, (c) at amino acids 2 and 18 of SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO:6, (d) at amino acids 4 and 16 of SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO:6, (e) at amino acids 4 and 16 of any one of SEQ ID NO: 5-24, or (f) at amino acids 4 and 16 of any one of SEQ ID NO: 5-24, and cyclization can occur via a tandem thiol SNAr reaction with hexafluorobenzene.
- Lys/Asp side chain-to-side chain cyclization and Glu/Lys side chain-to-side chain cyclization is routinely performed in the art, as are many other well-known approaches.
- the peptides of this disclosure may be in the form of any pharmaceutically acceptable salt.
- Acid addition salts of the peptides of this invention are prepared in a suitable solvent from the peptide and an excess of an acid, such as hydrochloric, hydrobromic, sulfuric, phosphoric, acetic, trifluoroacetic, maleic, succinic or methanesulfonic.
- suitable pharmaceutically acceptable salts may include alkali metal salts, such as sodium or potassium salts, or alkaline earth metal salts, such as calcium or magnesium salts.
- a conjugate comprises a peptide of the present disclosure conjugated to at least one additional domain.
- suitable additional domains include signal sequences, cell-penetrating or translocation domains, and marker domains.
- a conjugate can comprise a peptide described above in this section conjugated to a signal sequence.
- Transport of protein produced by transgenes to a subcellular compartment or for secretion is accomplished by means of operably linking the nucleotide sequence encoding a signal sequence to the 5′ and/or 3′ region of a gene encoding the protein of interest (i.e., a peptide of the present disclosure, or a derivative thereof).
- Targeting sequences at the 5′ and/or 3′ end of the structural gene may determine, during protein synthesis and processing, where the encoded protein is ultimately compartmentalized.
- the presence of a signal sequence directs a polypeptide to either an intracellular organelle or subcellular compartment or for secretion. Any signal sequence known in the art is contemplated by the present invention.
- a conjugate can comprise a peptide described above in this section conjugated to at least one marker domain.
- marker domains include fluorescent proteins, luciferase enzymes, purification tags, and epitope tags.
- the marker domain can be a fluorescent protein.
- Non limiting examples of suitable fluorescent proteins include green fluorescent proteins (e.g., GFP, GFP-2, tagGFP, turboGFP, EGFP, Emerald, Azami Green, Monomeric Azami Green, CopGFP, AceGFP, ZsGreenI), yellow fluorescent proteins (e.g., YFP, EYFP, Citrine, Venus, YPet, PhiYFP, ZsYellowI,), blue fluorescent proteins (e.g., EBFP, EBFP2, Azurite, mKalamaI, GFPuv, Sapphire, T-sapphire,), cyan fluorescent proteins (e.g.
- green fluorescent proteins e.g., GFP, GFP-2, tagGFP, turboGFP, EGFP, Emerald, Azami Green, Monomeric Azami Green, CopGFP, AceGFP, ZsGreenI
- yellow fluorescent proteins e.g., YFP, EYFP, Citrine, Venus, YPet, PhiYFP, ZsYellowI
- ECFP Cerulean, CyPet, AmCyanI, Midoriishi-Cyan
- red fluorescent proteins e.g., mKate, mKate2, mPlum, DsRed monomer, mCherry, mRFP1, DsRed-Express, DsRed2, DsRed-Monomer, HcRed-Tandem, HcRedI, AsRed2, eqFP61 1, mRasberry, mStrawberry, Jred
- orange fluorescent proteins e.g., mOrange, mKO, Kusabira-Orange, Monomeric Kusabira-Orange, mTangerine, tdTomato
- any other suitable fluorescent protein e.g., mOrange, mKO, Kusabira-Orange, Monomeric Kusabira-Orange, mTangerine, tdTomato
- the marker domain can be a luciferase enzyme.
- Non-limiting examples include firefly luciferase, Renilla luciferase, Nanoluc luciferase, and derivatives thereof.
- the marker domain can be a purification tag and/or an epitope tag.
- Exemplary tags include, but are not limited to, glutathione-S-transferase (GST), chitin binding protein (CBP), maltose binding protein, thioredoxin (TRX), poly(NANP), tandem affinity purification (TAP) tag, myc, AcV5, AU1, AU5, E, ECS, E2, FLAG, HA, nus, Softag 1, Softag 3, Strep, SBP, Glu-Glu, HSV, KT3, S, S1, T7, V5, VSV-G, 6 ⁇ His, biotin carboxyl carrier protein (BCCP), and calmodulin.
- the marker domain can be located at the N-terminus and/or the C-terminal of a peptide of the present disclosure.
- a conjugate can comprise a peptide described above in this section conjugated to at least one cell penetrating domain.
- the cell-penetrating domain can be a cell-penetrating peptide sequence derived from the HIV-1 TAT protein.
- the cell-penetrating domain can be TLM, a cell-penetrating peptide sequence derived from the human hepatitis B virus.
- the cell-penetrating domain can be MPG.
- the cell-penetrating domain can be Pep-1, VP22, a cell penetrating peptide from Herpes simplex virus, or a polyarginine peptide sequence.
- the cell-penetrating domain can be located at the N-terminus and/or the C-terminal of a peptide of the present disclosure.
- a peptide of the present disclosure can be conjugated to the at least one additional domain directly or indirectly.
- a conjugate comprises a linking group.
- a linking group may be any moiety that is at least bifunctional provided that the resulting link between the peptide and the additional domain is stable.
- Suitable linking moieties include bi- and multi-functional alkyl, aryl, aralkyl or peptidic moieties, alkyl, aryl, or aralkyl aldehydes acids esters and anhydrides, sulfhydryl or carboxyl groups, such as maleimido benzoic acid derivatives, maleimido propionic acid derivatives and succinimido derivatives or may be derived from cyanuric bromide or chloride, carbonyldiimidazole, succinimidyl esters or sulphonic halides and the like (Fischer et al., U.S. Pat. No. 6,472,507, the entire disclosure of which is incorporated herein by reference).
- the functional groups on the linker moiety may include amino, hydrazino, hydroxyl, thiol, maleimido, carbonyl, and carboxyl groups.
- the linker group is selected so as to be sufficiently labile (e.g., to enzymatic cleavage by an enzyme present in the targeted tissue) so that it is cleaved following transport of the peptide, thereby releasing the peptide.
- labile linkages are described in Low et al., U.S. Pat. No. 5,108,921, the entire disclosure of which is incorporated herein by reference.
- the conjugate may also dissociate by way of chemical cleavage between the peptide of the present disclosure and the additional domain.
- a conjugate is a fusion protein. In other embodiments, a conjugate comprises a non-peptide linking group.
- compositions which in some embodiments are suitable for pharmaceutical use.
- Such compositions typically comprise a peptide of this disclosure (including derivatives and conjugates thereof) and an acceptable carrier, for example one that is pharmaceutically acceptable.
- an acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration (Gennaro, Remington: The science and practice of pharmacy. Lippincott, Williams & Wilkins, Philadelphia, Pa. (2000)).
- Such carriers or diluents include, but are not limited to, water, saline, Finger's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. Except when a conventional media or agent is incompatible with an active compound, use of these compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
- a pharmaceutical composition is formulated to be compatible with its intended route of administration, including intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (i.e., topical), transmucosal, and rectal administration.
- Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose.
- the pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
- compositions suitable for injection include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
- suitable carriers include physiological saline, bacteriostatic water, CREMOPHOR ELTM (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
- the composition must be sterile and should be fluid so as to be administered using a syringe.
- Such compositions should be stable during manufacture and storage and must be preserved against contamination from microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (such as glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures.
- Proper fluidity can be maintained, for example, by using a coating such as lecithin, by maintaining the required particle size in the case of dispersion and by using surfactants.
- Various antibacterial and antifungal agents for example, parabens, chlorobutanol, phenol, ascorbic acid, and thimerosal, can contain microorganism contamination.
- Isotonic agents for example, sugars, polyalcohols such as manitol, sorbitol, and sodium chloride can be included in the composition.
- Compositions that can delay absorption include agents such as aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients as required, followed by sterilization.
- dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium, and the other required ingredients.
- Sterile powders for the preparation of sterile injectable solutions, methods of preparation include vacuum drying and freeze-drying that yield a powder containing the active ingredient and any desired ingredient from a sterile solutions.
- Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for administration as an aqueous or oily suspension, solution, emulsion, syrup or elixir. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included.
- Tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, PRIMOGEL, or corn starch; a lubricant such as magnesium stearate or STEROTES; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
- Liquid preparations may contain additives including, but not limited to, suspending agents, emulsifying agents, nonaqueous vehicles and preservatives.
- the compounds are delivered as an aerosol spray from a nebulizer or a pressurized container that contains a suitable propellant, e.g., a gas such as carbon dioxide.
- a suitable propellant e.g., a gas such as carbon dioxide.
- Systemic administration can also be transmucosal or transdermal.
- penetrants that can permeate the target barrier(s) are selected.
- Transmucosal penetrants include detergents, bile salts, and fusidic acid derivatives.
- Nasal sprays or suppositories can be used for transmucosal administration.
- the active compounds are formulated into ointments, salves, gels, or creams.
- the compounds can also be prepared in the form of suppositories (e.g., with bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
- suppositories e.g., with bases such as cocoa butter and other glycerides
- retention enemas for rectal delivery.
- the active compounds can also be are prepared with carriers that protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
- a controlled release formulation including implants and microencapsulated delivery systems.
- Biodegradable or biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Such materials can be obtained commercially from ALZA Corporation (Mountain View, Calif.) and NOVA Pharmaceuticals, Inc. (Lake Elsinore, Calif.), or prepared by one of skill in the art.
- Liposomal suspensions can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, such as in (Eppstein et al., U.S. Pat. No. 4,522,811, 1985).
- Unit dosage form refers to physically discrete units suited as single dosages for the subject to be treated, containing a therapeutically effective quantity of active compound in association with the required pharmaceutical carrier.
- the specification for the unit dosage forms are dictated by, and directly dependent on, the unique characteristics of the active compound and the particular desired therapeutic effect, and the inherent limitations of compounding the active compound.
- Nucleic acid molecules encoding peptides of the invention can be inserted into vectors and used as gene therapy vectors.
- Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (Nabel and Nabel, U.S. Pat. No. 5,328,470, 1994), or by stereotactic injection (Chen et al., Proc Natl Acad Sci USA. 91; 3054-7 (1994)).
- the pharmaceutical preparation of a gene therapy vector can include an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded.
- the pharmaceutical preparation can include one or more cells that produce the gene delivery system.
- Peptides of this disclosure can be made by chemical synthesis or by employing recombinant technology. These methods are well-known in the art. Chemical synthesis, especially solid-phase synthesis, is preferred for short (e.g., less than 50 residues) peptides or those containing unnatural or unusual amino acids. Recombinant procedures are preferred for longer peptides. When recombinant procedures are selected, a synthetic gene may be constructed de novo or a natural gene may be mutated by, for example, cassette mutagenesis.
- Recombinant DNA techniques for producing peptides of the present disclosure contemplate, in simplified form, taking the gene, either natural or synthetic, encoding the peptide; inserting it into an appropriate vector; inserting the vector into an appropriate host cell; culturing the host cell to cause expression of the gene; and recovering or isolating the peptide produced thereby.
- the isolated peptide is then purified to a suitable degree.
- DNA sequence encoding a peptide of the present disclosure can be cloned and manipulated (including but not limited to codon optimized) so that it may be expressed in a convenient host.
- DNA encoding a peptide of the present disclosure can be obtained by any method known in the art. See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual (2d ed.) (Cold Spring Harbor Laboratory: N.Y., 1989)).
- the DNA is then inserted into an appropriate plasmid or vector that is used to transform a host cell.
- plasmid vectors containing replication and control sequences derived from species compatible with the host cell are used in connection with those hosts.
- the vector ordinarily carries a replication site, as well as sequences encoding proteins or peptides that are capable of providing phenotypic selection in transformed cells.
- Preferred vectors can be constructed using standard techniques by combining the relevant traits of the desired vector. Relevant traits include but are not limited to a promoter, a ribosome binding site, polynucleotide sequence(s) encoding antibiotic resistance marker(s), appropriate origins of replication, and polynucleotide sequences encoding additional domains (including but not limited to signal sequences, targeting domains, cell-penetrating or translocation domains, and marker domains).
- the host cell may be prokaryotic or eukaryotic.
- the peptides When expressed by prokaryotes the peptides typically contain an N-terminal methionine or a formyl methionine and are not glycosylated.
- the N-terminal methionine or formyl methionine resides on the amino terminus of the fusion protein or the signal sequence of the fusion protein.
- a variation on the above procedures contemplates the use of gene fusions, wherein the gene encoding the desired peptide is associated, in the vector, with a gene encoding another protein or a fragment of another protein.
- the “other” protein or peptide can be a protein or peptide that can be secreted by the cell, making it possible to isolate and purify the desired peptide from the culture medium.
- the fusion protein can be expressed intracellularly. It is useful to use fusion proteins that are highly expressed.
- the use of gene fusions though not essential, can facilitate the expression of heterologous peptides as well as the subsequent purification of those gene products.
- the fusion protein may be cleaved to yield free peptide, which can be purified from the reaction mix.
- the cleavage may be accomplished using chemicals, such as cyanogen bromide, which cleaves at a methionine, or hydroxylamine, which cleaves between an Asn and Gly residue.
- the nucleotide base pairs encoding these amino acids may be inserted just prior to the 5′ end of the gene encoding the desired peptide.
- proteolytic cleavage of fusion protein Carter, in Protein Purification: From Molecular Mechanisms to Large - Scale Processes , Ladisch et al., eds.
- a peptide linker that is amenable to cleavage by the protease used is inserted between the “other” protein and the desired peptide.
- the nucleotide base pairs encoding the linker are inserted between the genes or gene fragments coding for the other proteins. Proteolytic cleavage of the partially-purified fusion protein containing the correct linker can then be carried out on either the native fusion protein, or the reduced or denatured fusion protein.
- peptides of the present disclosure can be conveniently prepared by solid-phase synthesis and purified according to methods known in the art. Any of a number of well-known procedures utilizing a variety of resins and reagents may be used to prepare the peptides of this disclosure. See, for example, Merrifield, J. Am. Chem. Soc., 85: 2149 (1964); Houghten, Proc. Natl. Acad. Sci. USA, 82: 5132 (1985)), although other equivalent chemical syntheses known in the art are employable. Solid-phase synthesis is typically initiated from the C-terminus of the peptide by coupling a protected ⁇ -amino acid to a suitable resin.
- Such a starting material can be prepared by attaching an ⁇ -amino-protected amino acid by an ester linkage to a chloromethylated resin or a hydroxymethyl resin, or by an amide bond to a BHA resin or MBHA resin.
- the preparation of the hydroxymethyl resin is described by Bodansky et al., Chem. Ind . (London), 38: 1597-1598 (1966).
- Chloromethylated resins are commercially available from BioRad Laboratories, Richmond, Calif. and from Lab. Systems, Inc. The preparation of such a resin is described by Stewart et al., Solid Phase Peptide Synthesis (Freeman & Co., San Francisco 1969), Chapter 1, pp. 1-6.
- BHA and MBHA resin supports are commercially available and are generally used only when the desired polypeptide being synthesized has an unsubstituted amide at the C-terminus.
- the amino acids are coupled to the peptide chain using techniques well known in the art for the formation of peptide bonds.
- One method involves converting the amino acid to a derivative that will render the carboxyl group more susceptible to reaction with the free N-terminal amino group of the peptide fragment.
- the amino acid can be converted to a mixed anhydride by reaction of a protected amino acid with ethylchloroformate, phenyl chloroformate, sec-butyl chloroformate, isobutyl chloroformate, pivaloyl chloride or like acid chlorides.
- the amino acid can be converted to an active ester such as a 2,4,5-trichlorophenyl ester, a pentachlorophenyl ester, a pentafluorophenyl ester, a p-nitrophenyl ester, a N-hydroxysuccinimide ester, or an ester formed from 1-hydroxybenzotriazole
- an active ester such as a 2,4,5-trichlorophenyl ester, a pentachlorophenyl ester, a pentafluorophenyl ester, a p-nitrophenyl ester, a N-hydroxysuccinimide ester, or an ester formed from 1-hydroxybenzotriazole
- Another coupling method involves use of a suitable coupling agent such as N,N′-dicyclohexylcarbodiimide or N,N′-diisopropyl-carbodiimide.
- a suitable coupling agent such as N,N′-dicyclohexylcarbodiimide or N,N′-diisopropyl-carbodiimide.
- Other appropriate coupling agents apparent to those skilled in the art, are disclosed in E. Gross & J. Meienhofer, The Peptides: Analysis Structure, Biology , Vol. 1: Major Methods of Peptide Bond Formation (Academic Press: New York, 1979).
- ⁇ -amino group of each amino acid employed in the peptide synthesis must be protected during the coupling reaction to prevent side reactions involving their active ⁇ -amino function.
- certain amino acids contain reactive side-chain functional groups (e.g., sulfhydryl, amino, carboxyl, and hydroxyl) and that such functional groups must also be protected with suitable protecting groups to prevent a chemical reaction from occurring at that site during both the initial and subsequent coupling steps.
- suitable protecting groups known in the art, are described in Gross and Meienhofer, The Peptides: Analysis. Structure, Biology, Vol. 3: “Protection of Functional Groups in Peptide Synthesis” (Academic Press: New York, 1981).
- An ⁇ -amino protecting group (a) must render the ⁇ -amino function inert under the conditions employed in the coupling reaction, (b) must be readily removable after the coupling reaction under conditions that will not remove side-chain protecting groups and will not alter the structure of the peptide fragment, and (c) must eliminate the possibility of racemization upon activation immediately prior to coupling.
- a side-chain protecting group (a) must render the side-chain functional group inert under the conditions employed in the coupling reaction, (b) must be stable under the conditions employed in removing the ⁇ -amino protecting group, and (c) must be readily removable upon completion of the desired amino acid peptide under reaction conditions that will not alter the structure of the peptide chain.
- protecting groups known to be useful for peptide synthesis will vary in reactivity with the agents employed for their removal.
- certain protecting groups such as triphenylmethyl and 2-(p-biphenylyl)isopropyloxycarbonyl are very labile and can be cleaved under mild acid conditions.
- Other protecting groups such as t-butyloxycarbonyl (BOC), t-amyloxycarbonyl adamantyl-oxycarbonyl, and p-methoxybenzyloxycarbonyl, are less labile and require moderately strong acids, such as trifluoroacetic, hydrochloric, or boron trifluoride in acetic acid, for their removal.
- Still other protecting groups such as benzyloxycarbonyl (CBZ or Z), halobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl cycloalkyloxycarbonyl, and isopropyloxycarbonyl, are even less labile and require stronger acids, such as hydrogen fluoride, hydrogen bromide, or boron trifluoroacetate in trifluoroacetic acid, for their removal.
- aromatic urethane-type protecting groups such as fluorenylmethyloxycarbonyl (FMOC) CBZ, and substituted CBZ, such as, e.g., p-chlorobenzyloxycarbonyl, p-6-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, and p-methoxybenzyloxycarbonyl, o-chlorobenzyloxycarbonyl, 2,4-dichlorobenzyloxycarbonyl, 2,6-dichlorobenzyloxycarbonyl, and the like; (b) aliphatic urethane-type protecting groups, such as BOC, t-amyloxycarbonyl, isopropyloxycarbonyl, 2-(p-biphenylyl)-isopropyloxycarbonyl, allyloxycarbonyl and the like; (c)
- the preferred ⁇ -amino protecting groups are BOC or FMOC; (2) for the side chain amino group present in Lys, protection may be by any of the groups mentioned above in (1) such as BOC, p-chlorobenzyloxycarbonyl, etc.; (3) for the guanidino group of Arg, protection may be by nitro, tosyl, CBZ, adamantyloxycarbonyl, 2,2,5,7,8-pentamethylchroman-6-sulfonyl, 2,3,6-trimethyl-4-methoxyphenylsulfonyl, or BOC; (4) for the hydroxyl group of Ser, Thr, or Tyr, protection may be, for example, by C1-C4 alkyl, such as t-butyl; benzyl (BZL); or substituted BZL, such as p-methoxybenzyl, p-nitrobenzyl, p-chlorobenzyl, o-chlorobenzyl, and 2,6-d
- the preferred protecting group is 2,6-dichlorobenzyl; (8) for the side-chain amino group of Asn or Gln, xanthyl (Xan) is preferably employed; (9) for Met, the amino acid is preferably left unprotected; (10) for the thio group of Cys, p-methoxybenzyl is typically employed;
- the C-terminal amino acid, e.g., Lys is protected at the N-amino position by an appropriately-selected protecting group, in the case of Lys, BOC.
- the BOC-Lys-OH can be first coupled to the benzyhydrylamine or chloromethylated resin according to the procedure set forth in Horiki et al., Chemistry Letters, 165-168 (1978) or using isopropylcarbodiimide at about 25EC for 2 hours with stirring.
- the ⁇ -amino protecting group is removed, as by using trifluoroacetic acid (TFA) in methylene chloride or TFA alone.
- TFA trifluoroacetic acid
- the deprotection is carried out at a temperature between about OEC and room temperature.
- Other standard cleaving reagents, such as HCl in dioxane, and conditions for removal of specific ⁇ -amino protecting groups are described in the literature.
- the remaining ⁇ -amino and side-chain protected amino acids are coupled stepwise within the desired order.
- some may be coupled to one another prior to addition to the solid-phase synthesizer.
- the selection of an appropriate coupling reagent is within the skill of the art. Particularly suitable as a coupling reagent is N,N′-dicyclohexyl carbodiimide or diisopropylcarbodiimide.
- Each protected amino acid or amino acid sequence is introduced into the solid-phase reactor in excess, and the coupling is suitably carried out in a medium of dimethylformamide (DMF) or CH 2 Cl 2 or mixtures thereof. If incomplete coupling occurs, the coupling procedure is repeated before removal of the N-amino protecting group prior to the coupling of the next amino acid.
- the success of the coupling reaction at each stage of the synthesis may be monitored. A preferred method of monitoring the synthesis is by the ninhydrin reaction, as described by Kaiser et al., Anal. Biochem, 34: 595 (1970).
- the coupling reactions can be performed automatically using well-known methods, for example, a BIOSEARCH 9500TM peptide synthesizer.
- the protected peptide Upon completion of the desired peptide sequence, the protected peptide must be cleaved from the resin support, and all protecting groups must be removed. The cleavage reaction and removal of the protecting groups is suitably accomplished simultaneously or stepwise.
- the bond anchoring the peptide to the resin is an ester linkage formed between the free carboxyl group of the C-terminal residue and one of the many chloromethyl groups present on the resin matrix. It will be appreciated that the anchoring bond can be cleaved by reagents that are known to be capable of breaking an ester linkage and of penetrating the resin matrix.
- the protected peptide-resin can undergo methanolysis to yield the protected peptide in which the C-terminal carboxyl group is methylated.
- the methyl ester is then hydrolyzed under mild alkaline conditions to give the free C-terminal carboxyl group.
- the protecting groups on the peptide chain then are removed by treatment with a strong acid, such as liquid hydrogen fluoride.
- a strong acid such as liquid hydrogen fluoride.
- a particularly useful technique for methanolysis is that of Moore et al., Peptides, Proc. Fifth Amer. Pept. Symp ., M. Goodman and J. Meienhofer, Eds., (John Wiley, N.Y., 1977), p. 518-521, in which the protected peptide-resin is treated with methanol and potassium cyanide in the presence of crown ether.
- Another method for cleaving the protected peptide from the resin when the chloromethylated resin is employed is by ammonolysis or by treatment with hydrazine. If desired, the resulting C-terminal amide or hydrazide can be hydrolyzed to the free C-terminal carboxyl moiety, and the protecting groups can be removed conventionally.
- the protecting group present on the N-terminal ⁇ -amino group may be removed preferentially either before or after the protected peptide is cleaved from the support.
- HPLC high-pressure liquid chromatography
- HPLC reversed-phase HPLC
- other known chromatographic techniques including but not limited to gel permeation, ion exchange, partition chromatography, affinity chromatography (including monoclonal antibody columns), or countercurrent distribution.
- Lys/Asp cyclization has been accomplished using Na-Boc-amino acids on solid-phase support with Fmoc/9-fluorenylmethyl (OFm) side-chain protection for Lys/Asp; the process is completed by piperidine treatment followed by cyclization.
- Glu and Lys side-chains also have been crosslinked in preparing cyclic peptides: the peptide is synthesized by solid-phase chemistry on a p-methylbenzhydrylamine resin. The peptide is cleaved from the resin and deprotected.
- the cyclic peptide is formed using diphenylphosphorylazide in diluted methylformamide.
- diphenylphosphorylazide for an alternative procedure, see Schiller et al., Peptide Protein Res., 25: 171-177 (1985). See also U.S. Pat. No. 4,547,489. Also useful are thiomethylene bridges. Lebl and Hruby, Tetrahedron Letters, 25: 2067-2068 (1984). See also Cody et al., J. Med. Chem., 28: 583 (1985). Cyclic peptides may be purified by gel filtration followed by reversed-phase HPLC or other conventional procedures. The peptides can be sterile filtered and formulated into conventional pharmacologically acceptable vehicles.
- the compounds may exist as diastereoisomers, enantiomers, or mixtures thereof.
- the syntheses described above may employ racemates, enantiomers, or diastereomers as starting materials or intermediates. Diastereomeric products resulting from such syntheses may be separated by chromatographic or crystallization methods. Likewise, enantiomeric product mixtures may be separated using the same techniques or by other methods known in the art.
- Each of the asymmetric carbon atoms, when present, may be in one of two configurations (R or S), and both are within the scope of the present invention.
- the peptides described in this invention may be isolated as the free acid or base or converted to salts of various inorganic and organic acids and bases. Such salts are within the scope of this invention. Examples of such salts include ammonium, metal salts like sodium, potassium, calcium, and magnesium; salts with organic bases like dicyclohexylamine, N-methyl-D-glucamine and the like; and salts with amino acids like arginine or lysine. Salts with inorganic and organic acids may be likewise prepared, for example, using hydrochloric, hydrobromic, sulfuric, phosphoric, trifluoroacetic, methanesulfonic, malic, maleic, fumaric acid, and the like. Non-toxic and physiologically-compatible salts are particularly useful, although other less desirable salts may have use in the processes of isolation and purification.
- a number of methods are useful for the preparation of the salts described above and are known to those skilled in the art. Examples include reaction of the free acid or free base form of the peptide with one or more molar equivalents of the desired acid or base in a solvent or solvent mixture in which the salt is insoluble; or in a solvent like water after which the solvent is removed by evaporation, distillation or freeze drying. Alternatively, the free acid or base form of the product may be passed over an ion-exchange resin to form the desired salt or one salt form of the product may be converted to another using the same general process.
- the present disclosure provides a nucleic acid sequence encoding a peptide of Section II(d), which can be readily determined by one of skill in the art.
- the present disclosure provides a vector comprising a nucleic acid sequence encoding a peptide of Section II(d).
- Suitable vectors include plasmid vectors, phagemids, cosmids, artificial/mini-chromosomes, transposons, and viral vectors. The choice of the vector will vary depending upon the intended use (e.g., stable transformation in bacterial cells, stable transformation in a mammalian cell, etc.).
- a nucleic acid sequence encoding a peptide of Section II(d) is present in a plasmid vector.
- Non-limiting examples of suitable plasmid vectors include pUC, pBR322, pET, pBluescript, pCAMBIA2300, pRI 101, pBI121, pPZP100, and variants thereof.
- a nucleic acid sequence encoding a peptide of Section II(d) is present in a viral vector.
- Suitable viral vectors include, but are not limited to, lentiviral vectors and adeno-associated viral vectors.
- a vector can comprise additional expression control sequences (e.g., enhancer sequences, Kozak sequences, polyadenylation sequences, transcriptional termination sequences, etc.), selectable marker sequences (e.g., antibiotic resistance genes), origins of replication, and the like.
- preferred linear and cyclic peptides of the present disclosure inhibit Tat-TAR interaction, inhibit TAR dependent transcription, inhibit LTR-dependent gene expression, inhibits TAR processing by DICER, increases host cell apoptosis upon viral infection, and/or reduces viral transmission. Inhibition can be complete or partial (e.g., a reduction of about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or more). Methods for determining the above are known in the art. Illustrative methods are also detailed in the Examples.
- peptides of the present disclosure that specifically bind to HIV-1 TAR can be used to inhibit the interaction between HIV Tat and HIV TAR.
- a method for inhibiting an interaction between HIV Tat and HIV TAR comprises admixing a peptide of Section II or a derivative or conjugate thereof, an HIV Tat protein, and HIV TAR.
- the ability to suppress or inhibit the interaction between Tat peptide and TAR can be evaluated using methods known in the art, such as by using ITC as previously shown. See, for example, Crawford et al., ACS Chem Biol, 2016, 11: 2206-2215.
- a method for inhibiting an interaction between HIV Tat and HIV TAR comprises contacting an HIV infected cell with a peptide of Section II, or a derivative or conjugate thereof.
- the virus is HIV-1.
- peptides of the present disclosure can be used to inhibit HIV proliferation (e.g., replication).
- the method comprises contacting an HIV infected cell with a peptide of Section II, or a derivative or conjugate thereof.
- the virus is HIV-1.
- hematopoietic cells e.g., MT-2 T-cell lymphoma cells, primary peripheral blood mononuclear cells (PBMCs), isolated macrophages, isolated CD4-positive T cells or cultured H9.
- PBMCs primary peripheral blood mononuclear cells
- human T cells may be acutely infected with HIV using titers known in the art to acutely infect cells in vitro, such as 10 4,5 TCID 50 /mL for HIV-1.
- the cells are then cultured in the presence of varying amounts of a test compound. Cultures are then assayed for HIV production (e.g.
- a measure of HIV replication in vivo includes, but is not limited to, viral load.
- peptides of the present disclosure, including derivatives and conjugates thereof, that specifically bind to HIV-1 TAR can be used for the treatment of diseases and conditions involving an HIV infection.
- the process comprises administering an effective amount of an active compound of the present disclosure (i.e., any peptide of the present disclosure, including derivatives and conjugates thereof, that specifically binds to HIV-1 TAR), or a pharmaceutical composition comprising an active compound, to an individual in need of such treatment.
- An individual who is in need of such treatment is an individual who is infected with HIV or an individual who is at risk of infection due to actual or suspected exposure to the virus.
- the individual is diagnosed with AIDS.
- the virus is HIV-1.
- the presence of HIV-1 can be readily detected by any means standard in the art, e.g., by obtaining a patient blood sample and assaying it in vitro for the presence of HIV-1.
- Prophylaxis is indicated in previously uninfected individuals after known or suspected acute exposure to HIV. Examples of such prophylactic use of an active compound may include, but is not limited to, prevention of virus transmission from mother to infant and other settings where the likelihood of HIV transmission exists, such as, for example, accidents in health care settings wherein workers are exposed to HIV-containing blood products.
- the amount of the active compound that will be effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, is and is determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation also will depend on the route of administration and the seriousness of the disease, disorder, or condition and is decided according to the judgment of the practitioner and each patient's circumstances.
- an effective amount of an active compound inhibits (i.e., slow to some extent and preferably stop) viral replication. In other embodiments, an effective amount of an active compound, inhibits (i.e., slow to some extent and preferably stop) HIV infection of uninfected cells. In some embodiments, an effective amount of an active compound reduces the number of HIV infected cells. In some embodiments, an effective amount of an active compound relieves to some extent one or more of the symptoms associated with the disorder. In some embodiments, an effective amount of an active compound reduces AIDS morbidity. In some embodiments, an effective amount of an active compound reduces AIDS mortality.
- the method comprises administering an effective amount of the compound, or a pharmaceutical composition comprising the compound, as described herein, in combination with one or more compounds selected from the group consisting of reverse transcriptase inhibitors, HIV-1 protease inhibitors, or fusion inhibitors (collectively referred to below as “conventional HIV drug”) to an individual in need of such treatment or prophylaxis.
- HIV-1 drugs For marketed conventional HIV-1 drugs, suitable doses and dosing protocols are recommended by the manufacturer and published, for example in the Physician's Desk Reference, 60th Edition (Thomson Healthcare, 2006), the entire disclosure of which is incorporated herein by, reference. For both marketed drugs and investigational HIV-1 drugs, suitable doses are recommended and published in the literature, in reports of clinical trials of the compounds. The person skilled in the art will refer to such sources in determining a suitable dosed dosing protocol for any particular indication. However, a possible advantage of the using the HIV-1 drug in combination with the compounds of the present disclosure is that it may be possible to use either or both of the compounds at a lower dose than would be possible if the compounds were used separately.
- treatment can result in a decrease in viral load, an increase in the subject's CD4+ cell count, a reduction in AIDS morbidity, a reduction in AIDS mortality, inhibition of HIV infection of uninfected cells, a reduction in the number of HIV infected cells, a decrease to some extent one or more of the symptoms associated with an HIV infection, and/or prevention of HIV transmission.
- An active compound of the present disclosure may be administered by any route, including oral, rectal, pulmonary, sublingual, and parenteral administration.
- Parenteral administration includes, for example, intravenous, intramuscular, intraarterial, intraperitoneal, intranasal, intravaginal, intravesical (e.g., to the bladder), intradermal, transdermal, topical or subcutaneous administration.
- treatment would be given at least once per day, typically once, twice, three times or four times per day with the doses given at equal intervals throughout the day and night in order to maintain a constant presence of the drug in order to suppress the virus and reduce the opportunity for development of resistance.
- One or more active compounds of the present disclosure may be administered simultaneously, by the same or different routes, or at different times during treatment.
- the peptides of the invention may also be prescribed to be taken in combination with conventional HIV drugs.
- active compound of the present disclosure and conventional HIV drugs may be administered simultaneously, by the same or different routes, or at different times during treatment.
- the dose of the conventional HIV drug selected will depend on the particular compound being used and the route and frequency of administration.
- treatment of the conventional HIV drug will also be given at least once per day, typically once, twice, three times or four times per day with the doses given at equal intervals throughout the day and night, although not necessarily according to the same schedule as the compound of the invention.
- the treatment may be carried out for as long a period as necessary. Typically it is contemplated that treatment would be continued indefinitely while the infection persists, although discontinuation might be indicated if the compounds no longer produce a beneficial effect, for example due to development of resistance by the viruses.
- the treating physician will know how to increase, decrease, or interrupt treatment based on patient response.
- an active compound according to the invention to obtain therapeutic benefit for treatment of an HIV infection will, of course, be determined by the particular circumstances of the individual patient including the size, weight, age and sex of the patient, the nature and stage of the disease, the aggressiveness of the disease, and the route of administration of the compound.
- a daily dosage from about 0.02 to about 50 mg/kg/day may be utilized, more preferably from about 0.1 to about 10 mg/kg/day. Higher or lower doses are also contemplated as it may be necessary to use dosages outside these ranges in some cases.
- the daily dosage may be divided, such as being divided equally into two to four times per day daily dosing. Suitable dosage ranges for intravenous administration are generally about 20-500 micrograms of active compound per kilogram body weight.
- Suitable dosage ranges for intranasal or inhaled administration are generally about 0.01 pg/kg body weight to 1 mg/kg body weight.
- the dosage unit is determined by means of a valve which delivers a metered amount.
- Units in accordance with the invention are typically arranged to administer a metered dose or “puff” which delivers an appropriate dose.
- the daily dose which may be administered in a single dose or as divided doses throughout the day.
- Suppositories generally contain active ingredient in the range of 0.5% to 10% by weight; oral formulations preferably contain 10% to 95% active ingredient.
- Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.
- the present disclosure also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention.
- a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention.
- TBP6.7-TAR Crystal Structure Reveals Novel RNA Recognition by a Privileged ⁇ -Hairpin Scaffold that Reads the TAR Major-Groove
- TAR binding protein 6.7 (TBP6.7) is a protein that blocks TAR binding to a Tat-derived peptide, and inhibits Tat-TAR dependent transcription in HeLa nuclear extracts. 12
- TBP6.7 ⁇ 2- ⁇ 3 loop of TBP6.7 (i.e., amino acids 41 to 59 of full-length TBP6.7, which corresponds to SEQ ID NO: 15) binds to the TAR bulged stem-loop.
- TBP6.7 adopts the same classical RRM fold as parental U1A 11 (C ⁇ rmsd 0.85 ⁇ ), but RNA recognition differs distinctly.
- U1A uses RNP2 and RNP1 amino acids to recognize the single-stranded U1hpII loop ( FIG. 3B ).
- Y13 and F56 of U1A stack on Cyt10 and Adel 1
- TBP6.7 comparably stacks Y13 of RNP2 on Ade25 ( FIG. 3C ).
- the double-helical fold of the TAR RNA structure prevents analogous RNP1 interactions, leaving F56 of TBP6.7 exposed.
- TBP6.7 Like U1A, Q54 of TBP6.7 recognizes a 2′-OH (Gua34) whereas nearby R52 of RNP1 reads out O6 and N7 of Gua36 in TAR's major groove. Notably, R52 of U1A likewise reads N1 of Ade6 in the RNA loop and N7 in the stem-closing pair Gua16-Cyt5, but this is as close to base-specific readout by Arg as U1A gets. Importantly, the TBP6.7 ⁇ 2/ ⁇ 3 loop conformation is altered substantially relative to U1A (3.5 ⁇ C ⁇ rmsd), due to changes that fine-tune it for TAR duplex recognition.
- TBP6.7 binds TAR in a unique manner based primarily on a privileged ⁇ -hairpin scaffold selected to bind a duplex, rather single-stranded RNA recognition by RNP motifs.
- the observed TAR conformation is consistent with the Tat-peptide-bound state, characterized by a Uri23.Ade27-Uri38 triple ( FIG. 1B ) and bulged Cyt24 & Uri25 33, 34 .
- an unusual cross-loop Cyt30-Gua34 base pair is also seen ( FIG. 1A and FIG. 3C , yellow box), consistent with prior chemical probing, modeling, NMR intermediate analysis, base-pairing requirements for cyclin T1 binding, and TAR sequences needed for Tat-mediated transcription 58, 110-112 .
- the TBP6.7-TAR structure nicely explains TAR mutagenesis data ( FIG. 4E and FIG. 4F ).
- mutant hp1 is rationalized by the binding pocket it establishes for R47 ( FIG. 1B ).
- hp2 & hp4 are detrimental because each mutant abolishes the cross-loop Cyt30-Gua34 pair, thus disrupting the Gua34-to-R52 cation- ⁇ stack and underlying R52 readout of the Gua36 Hoogsteen edge ( FIG. 3C and FIG. 1B ); the latter recognition is ablated by mutants hp5 & hp6.
- TAR recognition is achieved principally by an evolved ⁇ 2- ⁇ 3 loop, wherein three Arg residues read the Hoogsteen edges of opposing guanines, with simultaneous cation- ⁇ stacking and salt-bridge formation to the RNA backbone ( FIG. 1B ). Additional protein-RNA interactions (also involving the ⁇ 2- ⁇ 3 loop) appear to add specificity ( FIG. 1A ), whereas evolved protein-protein interactions stabilize the ⁇ 2- ⁇ 3 loop conformation (e.g., Thr50-Arg52).
- Untagged TBP6.7 was next evaluated for TAR binding using Isothermal Titration calorimetry (ITC). Additionally, point mutants Y31H and Q36R were added to TBP6.7, which facilitated prior U1A crystallization efforts. These surface mutants are distant from the TAR binding face, and we observe them in crystal contacts between TBP subunits. Notably, the extraordinarily high affinity of the TBP6.7-TAR complex requires special consideration to attain an even distribution of injection heats throughout the inflection point of the thermogram for accurate curve fitting 113 . At 20° C., the thermogram was too steep, allowing only a K D estimate of ⁇ 0.7 nM (not shown). At 37° C. curve fitting is reliable resulting in a K D of 18.5 ⁇ 1.4 nM ( FIG.
- the higher temperature of ITC accounts for K D differences with SPR, which was done at 20° C. ( FIG. 4D and ref. 12 ).
- the results demonstrate exceptionally tight binding.
- a fusion protein was created comprising the TBP6.7 ⁇ 2- ⁇ 3 hairpin ( FIG. 6A ) linked by flexible, soluble spacer (GGS) 3 to SUMO (Small Ubiquitin-like Modifier), a 12 kDa protein that expresses well in E. coli and stabilizes a variety of structurally diverse fusion proteins.
- the affinity for TAR was then measured by ELISA ( FIG. 6B ).
- SUMO does not have appreciable TAR binding, but the SUMO- ⁇ 2- ⁇ 3 hairpin fusion binds TAR.
- the ⁇ 2- ⁇ 3 hairpin fusion shows no appreciable affinity for U1hpII or BIV TAR ( FIG. 6B ). This demonstrates selectivity for HIV TAR is retained.
- Peptides of the present disclosure are prepared by SPPS using standard protocols 136 , on an automated SPPS instrument. Multiple cyclization strategies are employed. Suitable strategies allow for efficient synthesis and produce peptides that retain TAR affinity. Peptides having a full length ⁇ -loop structure (e.g. SEQ ID NO: 5-24) and truncations (e.g., shorter or no ⁇ -strands) are evaluated.
- a full length ⁇ -loop structure e.g. SEQ ID NO: 5-24
- truncations e.g., shorter or no ⁇ -strands
- Cyclic peptides of the size described in this disclosure are prepared by a number of methods. 136, 137
- N- to C-cyclization is employed following previous methods 138 , from linear peptides representing residues 41-59 (i.e., retaining the full ⁇ 2 and ⁇ 3 strands, FIG. 6A ) or 44-56 (i.e., truncated ⁇ -strands). If N-to-C cyclization changes H-bonding in the ⁇ 2- ⁇ 3 strand ( FIG. 2 ), thereby altering the positioning of loop residues that engage TAR, alternative strategies are used.
- Residues D42/I58 or L44/F56 (which occupy the same face of ⁇ 2- ⁇ 3 mini-sheet, and are thus well positioned for conjugation) can be replaced with cysteine residues and cyclization can be engaged via a tandem thiol S N Ar reaction with hexafluorobenzene ( FIG. 7 , only the C42/C58 mutant is shown)—an approach reported previously as selective for cysteine-mediated peptide ‘stapling’ and cyclization 139, 140 . This reaction is assessed in solution and on solid support (as part of SPPS).
- the N-terminus and C-terminus are modified to retard degradation by peptidases.
- the N-terminus is methylated and the C-terminus is converted to an amide using standard procedures.
- Cyclic peptides are HPLC purified and composition verified by mass spectrometry.
- Affinity between cyclic peptides and TAR are assessed by ELISA as shown 12 (see FIG. 4C ). Affinity of the tightest binding cyclic peptides are quantitated by SPR and ITC as shown 12 ( FIG. 4D and FIG. 5 ). Binding selectivity for the tightest TAR binders are assessed with ELISA as shown 12 ( FIG. 4F ), by comparison to U1hpII and BIV TAR. Cyclic peptides with the best TAR affinity and selectivity profiles are then assessed for the ability to suppress or inhibit the interaction by Tat peptide and TAR, using ITC as previously shown. 12 Finally, selected cyclic peptides are assessed for the ability to suppress Tat-TAR dependent transcription in HeLa cell lysate, as previously shown. 12
- cyclic peptides are evaluated for each cell line employed including: 293T, HeLa, and peripheral blood mononuclear cells (PBMCs).
- PBMCs peripheral blood mononuclear cells
- the CellTiter 96® AQueous One Solution Cell Proliferation Assay or MTS (Promega) in which a tetrazolium compound is bioreduced to a colored formazan product by metabolically active cells is used.
- This assay is used to eliminate cyclic peptides that are overtly toxic prior to infectivity analysis.
- This assay is routinely used to assess toxicity in mammalian cells following biologic treatment. 70, 74, 78, 79, 81, 82, 142
- cyclic peptide uptake by cells is measured, as well as the percent residence within endosomes or the cytosol.
- the prevalence of arginine in the ⁇ -loops suggests that these cyclic peptides will be cell penetrating. If not, the addition of as few as three arginines into the cyclic system has been shown to promote penetration of mammalian cells by cyclic peptides 146 .
- fluorescein functionalized cyclic peptides are used. Fluorescein conjugated cyclic peptides are prepared by SPPS. A ⁇ -strand residue or a penultimate residue is mutated to lysine, which is conjugated readily to a commercially available fluorescein NHS-ester using standard methods.
- fluorescein conjugated cyclic peptides are incubated with CD4-positive T-cells (Jurkat), which are representative of the cellular targets for the therapeutic leads. Following incubation, cells re washed with a PBS/heparin sulfate solution, which has been used to remove cell surface bound polypeptides. 70, 78, 79, 80-82 Fluorescence microscopy is used initially to determine if the cyclic peptides penetrate cells; an absence of punctuate foci supports residence in the cytoplasm. Using a technique previously used 70, 151 , it is directly measured whether internalized cyclic peptides reside in endosomes or within the cytosol.
- cells are lysed with digitonin, which disrupts the cell membrane but not endosomes.
- lysate are blotted onto nitrocellulose and incubated separately with anti-fluorescein, anti-Erk/1/2 (a cytosolic marker) or Rab5 (an endosomal marker).
- anti-fluorescein, anti-Erk/1/2 a cytosolic marker
- Rab5 an endosomal marker
- Lysis generated from RIPA buffer (which disrupts both the cell membrane and endosomes) are used as a control to reveal material that resides only in endosomes. While most cyclic peptides of the type and size presented here penetrate mammalian cells placing them in the cytosol, if the cyclic peptides are not cell-penetrating, or reside in endosomes, cell-penetrating and/or endosomolytic sequences 155 are conjugated to the peptides (opposing the ⁇ 2- ⁇ 3 loop).
- Cyclic peptides are validated for the mechanism of action (MOA) based on their dose-dependent ability to: (i) inhibit Tat-mediated LTR-driven expression of luciferase in TZM-bl HeLa reporter cells following infection with pseudotyped HIV; (ii) inhibition of Tat-mediated elongation of full-length viral transcripts in HEK293T producer and TZM-bl reporter cells 156 ; and (iii) inhibition of live virus in spreading infection assays.
- MOA mechanism of action
- the pseudotyped HIV proviral vector encodes all HIV genes but nef (replaced by EGFP) and env. This enables dose-dependent determination of cyclic peptide competition with Tat by quantifying: (i) full-length viral transcripts in 293T and TZM-bl cells using primers comprising polyA and upstream viral sequences to prime RT-PCR 157 , (ii) viral particle yield (p24 detection), and (iii) effects on viral particle integrity (i.e., based on their infectivity of TZM-bl cells not treated with peptides). These experiments establish the MOAs, and provide controls prior to single-round infectivity and live-virus testing.
- HEK 293T producer cells (standard in the field) are transfected with proviral vector and trans complementing cDNAs that provide envelope functionality. Viral particles are harvested from media 24 hr after transfection by 0.45- ⁇ m filtering. Viral load for infection of TZM-bl cells are normalized by p24 ELISA (Perkin Elmer). The ability of cyclic peptides to compete with Tat—expressed by these virions following TZM-bl infection—is determined by treating cells with a seven-point dose range of each cyclic peptide (100 nM to 25 ⁇ M) prior to infection; 6, 12, 24 and 48 hr post-infection cells are quantified for luciferase expression.
- This assay is conducted to identify cyclic peptides vetted by single-cycle infectivity (above) that show dose-dependent antiviral activity with a high therapeutic index (efficacy/toxicity).
- the activity of cyclic peptides is evaluated against isolates from 9 viral clades with different tropisms, along with 7 single- and multi-drug resistant strains. Briefly, cyclic peptides with the maximum Tat-dependent antiviral activity (above) are assayed in a standard spreading infection of pooled PBMCs using live HIV-1. Test cPepTb dilutions are prepared at a 2 ⁇ concentration and 100 ⁇ L of each concentration placed in appropriate wells.
- the TAR fold herein is consistent with prior structural features observed by NMR for TAR complexes with small-molecules.
- the TAR 27-mer comprises helical stems S1a and S1b interrupted by the Uri23.Ade27-Uri38 triple.
- the flanking UCU-bulge extrudes bases Cyt24 and Uri25 from the duplex core, consistent with solution studies.
- the apical loop exhibits a canonical Cyt30-Gua34 pair separated from S1b by bulged base Ade35. Hexaloop bases Gua32 and Uri31 stack on Cyt30, whereas Gua33 projects outward.
- the apical loop features of the co-crystal structure agree well with NMR assignments, chemical probing, modeling, sequence conservation, and the requirement of the Cyt30-Gua34 base pair for TAR binding to cyclin-T1.
- TBP6.7 binds the TAR duplex at S1b burying 1555 ⁇ 2 , whereas U1A recognizes mostly single-stranded RNA in the U1hpII loop between Ade66 and C72.
- the preponderance of specific contacts to TAR originates from the ⁇ 2- ⁇ 3 loop.
- the Q54 amide of U1A RNP1 approaches the 2′-OH of Gua69 in U1hpII but does not interact, whereas the amide NO of TBP6.7 H-bonds to the 2′-OH of Gua34 in TAR—consistent with its role in RNA readout in other RRMs.
- R52 of RNP1 recognizes the Hoogsteen edge of the loop-closing pair Gua76-Cyt65 in U1hpII, as well as Gua36 in TAR.
- the former interaction is the only instance of Arg-mediated base readout by U1A, and its simultaneous recognition of Ade66 N1 yields a non-optimal, inclined guanidinium-guanine interaction.
- TBP6.7 utilizes its RNP motifs to bind the TAR duplex, although the preponderance of its affinity and specificity appears to arise from contacts contributed by the evolved ⁇ 2- ⁇ 3 loop, thus distinguishing it from U1A.
- TBP6.7 Specificity Relies on Three Arginines to Read the TAR Major Groove ITC analysis of the TBP6.7-TAR complex showed a K D,App of 2.5 ⁇ 0.1 nM (Table 2), consistent with tight binding measured by surface plasmon resonance. From the analysis of the co-crystal structure, binding interactions were parsed into four groups: (i) ⁇ 2- ⁇ 3 loop arginines that read major-groove guanines to impart specificity; ⁇ 2- ⁇ 3 loop residues that add affinity by interaction with the backbone or 2′-OH groups; (iii) evolved protein-protein interactions that stabilize the ⁇ 2- ⁇ 3 loop; and (iv) interactions outside the ⁇ 2- ⁇ 3 loop that impart affinity. Mutants from each category were prepared to test specific structural observations. Each amino acid was changed to Ala to disrupt TAR binding without the potential to form new interactions.
- R52 exhibits the fewest interactions with TAR, making it straightforward to assess their energetic contributions to binding.
- the guanidinium group donates H-bonds from NH1 and NH2 to the N7 and O6 moieties of Gua36, while forming a cation- ⁇ interaction involving C ⁇ and the imidazole of Gua34 in the apical loop.
- R52A reduced binding by a factor of 116, resulting in a ⁇ G of +2.8 kcal mol ⁇ 1 . This value is consistent with prior observations that suggest a single H-bond contributes ⁇ 0.5 kcal mol ⁇ 1 and a cation- ⁇ interaction is worth ⁇ 1.8 kcal mol ⁇ 1 .
- R49 of TBP6.7 is the only arginine that resulted from selection. Its side-chain makes more contacts to TAR than R47 by positioning the guanidinium group to form H-bond and salt-bridge contacts that readout N7 and the pro-R p backbone oxygen of Gua28, while forming a cation- ⁇ contact with Ade27. As such, R49A TBP6.7 mutant yielded a ⁇ G of +3.3 kcal mol ⁇ 1 , corresponding to a loss in binding by a factor of 284 (Table 2).
- the energetic loss is consistent with the observed structural interaction comprising: a H-bond of ⁇ 0.5 kcal mol ⁇ 1 ; an exposed salt-bridge of ⁇ 1 kcal mol ⁇ 1 ; and a non-optimal cation- ⁇ contact between C ⁇ of R49 and the Ade27 imidazole worth ⁇ 1.8 kcal mol ⁇ 1 .
- R47 is present in the U1A sequence but it does not make contacts to the U1hpII RNA.
- R47 of TBP6.7 makes the most extensive number of contacts with TAR relative to any arginine in the co-crystal structure.
- the R47 guanidinium forms ‘arginine fork’ interaction whereby NH1 and NH2 groups H-bond to O6 and N7 of the Gua26 base, while its N ⁇ and NH2 groups form H-bond and salt-bridge contacts to O5′ and the pro-R p oxygen of Uri23. Simultaneously, the guanidinium is sandwiched between the bases of Ade22 and Uri23 forming cation- ⁇ interactions consistent with other protein-RNA complexes.
- the mutant side-chain is likely too short to interact with TAR, but binding was lowered by a factor of only 1.4, resulting in a subtle ⁇ G increase of +0.2 kcal mol ⁇ 1 (Table 2). This small change and the ability of T48 O ⁇ 1 to form an H-bond suggest a favorable new interaction likely occurs.
- Q54 of TBP6.7 was next evaluated because it binds TAR at the 2′-OH group of Gua34 of the apical loop, noted as an RNP1 interaction.
- the loss in binding for Q54A TBP6.7 mutant was only a factor of 2.2 with a ⁇ G of +0.5 kcal mol ⁇ 1 (Table 2), consistent with a single H-bond.
- Such amino acids are consistent with individual H-bond interactions that recognize RNA backbone or sugar features, rather than sequence specific readout observed for R47, R49 or R52.
- T50 of TBP6.7 was examined.
- T50 of TBP6.7 forms an H-bond to N ⁇ of R52 that steers the guanidinium group into the Gua36 Hoogsteen edge.
- the T50A TBP6.7 mutant reduces binding by a factor of four with a ⁇ G of +1.0 kcal mol ⁇ 1 (Table 2), consistent with the greater strength of neutral-to-charged H-bonds interactions.
- the U1A C-terminus forms a short helix that interacts with U1hpII at residues 91, 92 and 94. These positions were diversified and subjected to selection, but no clear consensus emerged.
- the co-crystal structure revealed no appreciable interaction between the TBP6.7 C-terminus and RNA. To corroborate this observation, we truncated TBP6.7 after residue 90. ITC analysis revealed a reduction in binding by a factor of 3.9, and a ⁇ G of +0.8 kcal mol ⁇ 1 (Table 2).
- K91 makes van der Waals contacts to F56 of RNP1, and R52 makes H-bonds to the carbonyl oxygen of nearby K60, which likely favor the core fold.
- Minimal TAR-Binding Peptides Retain HIV-1 TAR-Binding Function The TBP selection approach 12 led to the identification of a privileged peptide sequence for high-affinity TAR recognition. It was then discovered that RNA specificity is achieved primarily by three arginines and flanking residues in the ⁇ 2- ⁇ 3 loop. The loop conformation is stabilized by evolved residues P46, T50, P51, and an intra-amino acid H-bond between the R49 carbonyl oxygen and its NH1 moiety. This loop joins antiparallel ⁇ -strands with typical backbone H-bonding, and hydrophobic side-chain packing. As such, we hypothesized that the ⁇ 2- ⁇ 3 loop is a supersecondary structure capable of binding TAR RNA outside the context of the TBP6.7 protein.
- TAR binding by the isolated ⁇ 2- ⁇ 3 loop sequence we first fused this short peptide to SUMO (Small Ubiquitin-like Modifier). The results revealed that TAR binds the ⁇ 2- ⁇ 3 loop when fused to SUMO, whereas non-cognate RNA sequences, such as BIV TAR and U1hpII, did not elicit significant binding. As expected, SUMO alone showed no appreciable RNA binding, whereas U1A produced the highest relative level of binding to its cognate target, U1hpII, but did not interact with BIV or HIV TAR. Arg-to-Ala mutants were then tested.
- SUMO Mall Ubiquitin-like Modifier
- the R47A, R49A and R52A mutants each lowered the extent of SUMO- ⁇ 2- ⁇ 3 loop binding to HIV TAR, and did not enhance interactions with non-cognate RNAs. These data suggest that the isolated ⁇ 2- ⁇ 3 loop interacts with HIV TAR in the arginine-dependent manner established by the co-crystal structure.
- a “stapled” peptide variant of the ⁇ 2- ⁇ 3 loop was prepared on the E. coli surface.
- the cyclic peptide produced a K D,App of ⁇ 80 nM, whereas BIV TAR and U1hpII RNAs did not interact appreciably.
- Stapled peptides harboring R47A, R49A or R52A mutations were each impaired in their ability to bind HIV TAR, supporting the mode of peptide-RNA binding in the co-crystal structure.
- TAR-peptide complexes show a variety of low-energy conformations in the solution ensemble in which distinct arginines alternate between RNA-bound and free states.
- MD molecular dynamics
- the average occupancy of interactions were quantified over multiple trajectories spanning a total of >20 ⁇ s.
- trajectories were ran on: (i) isolated TAR RNA; (ii) TAR-TBP6.7; and (iii) TAR-( ⁇ 2- ⁇ 3 loop cyclic peptide).
- each arginine recognizes a specific guanine in the major groove but also utilizes conformational features of TAR, such as the U ⁇ A-U triple and apical loop that distinguish it from A-form duplexes.
- TBP6.7 appears to avoid interactions with other RNAs such as Bovine immunodeficiency virus TAR and U1hpII.
- each arginine of the TBP6.7 ⁇ 2- ⁇ 3 loop recognizes a strictly conserved guanine in TAR, suggesting that TAR RNA recognition by TBP6.7 will be preserved over most HIV-1 clades and circulating recombinant forms.
- TBP6.7 and mutants thereof were prepared by production of a synthetic gene based on the human U1A sequence used in structural studies including crystallization mutants Y31H and Q36R.
- TAR strands ranging in size from 25 to 31-mers were produced by chemical synthesis (GE Lifesciences), and purified by denaturing PAGE. Lyophilized RNA was suspended in a folding buffer comprising 0.050 M Na-HEPES pH 7.0 containing 0.10 M NaCl. The RNA was heated to 65° C. for 5 min followed by addition of 0.006 M MgCl 2 before slow cooling. Samples were then incubated at 37° C.
- ITC Isothermal titration calorimetry
- RNA was diluted with dialysis buffer to 3.1-3.3 ⁇ M for wild type Fpr, 3.2-7.8 ⁇ M for the A52G and A84G Fpr mutants, 10.5-15.7 ⁇ M for the C7U and U17C Fpr mutants, 2.4-3.6 ⁇ M for 74 env, and 1.8 ⁇ M for 74 env-s2 ⁇ 30-43.
- PreQ 1 was dissolved in dialysis buffer at concentrations ⁇ 10-fold higher than RNA. Thermograms were analyzed with Origin 7.0 (MicroCal) using a 1:1 binding model. Average thermodynamic parameters and representative thermograms with curve fits are provided (Table 2).
- TAR RNA was dissolved to 0.16 mM in 0.010 M Na-cacodylate pH 7.0.
- RNA was folded by heating to 65° C. for 3 min followed by addition of 0.006 M MgCl 2 and 0.32 mM preQ 1 ; subsequently, the RNA was heated to 65° C. for 5 min, followed by slow cooling and 0.2 ⁇ m filtration.
- Crystals were prepared by the hanging drop vapor-diffusion method in which 1.6-2.0 ⁇ L of folded RNA was mixed with an equal volume of well solution, followed by equilibration over 1 mL of well solution at 20° C.
- Crystals grew as isosceles trapezoidal plates within 3 d and achieved a maximum size of 0.2 mm ⁇ 0.2 mm ⁇ 0.015 mm within 3 weeks.
- the well solution used to prepare a ‘native’ crystal of the PM construct with a G ⁇ U pair was 74.5% Tacsimate pH 7.0 (Hampton Research), 0.050 M MOPS pH 7.0, 0.020 M Co(NH 3 ) 6 Cl 3 , and 0.001 M spermine ⁇ HCl.
- the well solution used to prepare a heavy-atom-derivatized PM crystal contained 1.9 M Na-malonate pH 7.0 (Hampton Research), 0.20 M CsCl 2 , 0.050 M Na-MOPS pH 7.0, 0.050 M Mg(C 2 H 3 O 2 ) 2 , and 0.001 M spermine ⁇ HCl. Crystals of the wild type sequence used for “high-resolution” refinement were prepared from a well solution of 85% Tacsimate pH 7.0, 0.010 M Mg(C 2 H 3 O 2 ) 2 , 0.006 M Co(NH 3 ) 6 Cl 3 , and 0.001 M spermine ⁇ HCl.
- Phase Determination, Refinement, and Analysis Phases were obtained by molecular replacement in Phenix starting from the U1A coordinates devoid of U1hpII. Phenix.AutoBuild (42) was used to trace the backbone, followed by iterative use of Phenix.refine interspersed with manual building in Coot. The resolution of the structure was extended to 2.75 ⁇ resolution using data from an isomorphous crystal with the wild type Fpr sequence. The structure converged on R cryst /R work /R free values of 21.4%/21.2%/22.8% with acceptable geometry, and a clash score of 1.24 (Table 1).
- the quality of the refined structure is indicated by the clear electron density for all nucleotides, except a break at positions 34 and 35 within the P3 loop.
- PreQ 1 is visible in omit and unbiased electron density maps that define its placement in the structure; the ligand-binding pocket is free from crystallographic contacts.
- SUMO is 12 kDa protein that expresses well in E. coli and stabilizes a variety of diverse fusion proteins.
- a ⁇ 2- ⁇ 3 loop peptide comprising the sequence L 41 -to-F 59 —or mutants thereof—was fused to a flexible GGS linker at the SUMO C-terminus, and RNA binding was measured by ELISA.
- a cyclized variant comprising the ⁇ 2- ⁇ 3 loop peptide was displayed on the surface of E. coli by fusion to the cell-surface protein OmpX by an intervening (GGS) 3 linker harboring a TEV protease site.
- Stapling was accomplished by inserting nucleophiles using L44C and F56C mutations. Following treatment with a reducing agent (DTT), chemical cyclization was achieved by SNAr conjugation using polyfluorinated biarylsulfoxide; ⁇ 2- ⁇ 3 loop peptides with R-to-A mutations were prepared similarly. RNA affinity was then measured by flow cytometry at 25° C. more than three times. The peptide product was subjected to TEV cleavage and the product was verified by mass spectrometry. E. coli displaying OmpX alone did not show appreciable TAR binding.
- DTT reducing agent
- Toxicity of cyclic peptides that specifically bind to TAR are assessed in balb/c mice by a dose-escalation schema starting at an initial intravenous (tail vein) dose of 20 ⁇ g/mouse ( ⁇ 1 mg/kg) and increasing in an accelerated format until gross toxicity is observed or dosing is limited by other factors. Toxicity in groups of 3 treated mice are determined grossly by monitoring mouse weight in each treatment cohort a minimum of 3 ⁇ weekly following a single dose. At sacrifice, heart, liver, colon, lung, spleen and kidney are collected for histopathologic evaluation by a board certified veterinary pathologist. All sections are scored based on overall percentage of tissue affected as well as degree of individual cellular alterations.
- a score of 1-4 can be assessed for ⁇ 25%, 26-50%, 51-75%, and 75-100% tissue involvement, while a score of 1-3 can be assessed for mild, moderate, and marked cellular alterations.
- Cardiomyocyte changes assessed include: myocytic vacuolar degeneration, myocytolysis, myofibril atrophy, and fibrosis.
- Hepatocyte changes assessed include: hydropic and vacuolar degeneration.
- Tissues for toxicity assessment can be collected from animals 5 days post-dosing. Toxicity is assessed following a multiple-dosing protocol following pharmacokinetic (PK) evaluation and establishment of a presumed dosing schema (how much/how often) to test therapeutic efficacy. These multiple-dosing studies are done in cohorts of 5 mice using the PK calculated doses and schedule.
- PK pharmacokinetic
- Serum stability is determined by incubation in mouse serum and determining levels over time by analytical methods (below).
- the PK of single-doses is carried out in balb/c mice using 3 doses determined to be safe based on toxicity (above). Cyclic peptides are administered intravenously (tail vein) and blood collected at 5, 15, 30, 60, 120, 240, 480, 720 and 1440 min by cardiac stick exsanguination under isoflurane anesthesia. Three mice are used per time point per dose and PK analysis is done using the combined animal data (“super-mouse” model).
- Peptide levels are measured based on amounts of administered cyclic peptide by LC/MS/MS with inclusion of stable isotope-labeled residues and control peptides in the assay protocol. All analytical methodology are validated in matrix (mouse plasma) with quality assurance (QA) and quality control (QC) samples included in each batch. PK data is analyzed by an appropriate modeling method (compartmental or non-compartmental) using Phoenix WinNonlin v.6.3 (Pharshight, St. Louis Mo.). The resulting PK data is used to determine a multiple dosing protocol for toxicity studies.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
TABLE 1 | ||
TBP6.7-TAR X-ray diffraction and refinement statistics | ||
Data Collectiona | ||
Wavelength (Å) | 0.9795 | ||
| P4 | 3212 | |
Cell Constants | |||
a = b, c (Å) | 40.4, 284.6 | ||
α = β = γ (°) | 90.0 | ||
Resolution (Å) | 38.90-1.80 | ||
(1.83-1.80) | |||
Rp.i.m. (%)b | 2.6 (45.1) | ||
CC1/2 (%)c | 98.7 (69.2) | ||
I/σ(I) | 19.9 (1.8) | ||
Complete (%) | 99.4 (91.8) | ||
Redundancy | 8.8 (7.9) | ||
Refinement | ||
Resolution (Å) | 37.2-1.80 | ||
No. reflections | 23297 | ||
Rwork/Rfree (%) | 18.5/21.0 | ||
RMSD | |||
bonds (Å) | 0.014 | ||
angles (°) | 1.60 | ||
Clash Scored | 2.9 | ||
Ramachandran (%) | |||
Allowed | 98.9 | ||
Outliers | 1.1 | ||
Coord. Errord (Å) | 0.19 | ||
aX-ray data collection was conducted remotely at the Stanford Synchrotron Radiation | |||
Lightsource (Menlo Park, CA) using Blu-Ice software and the Stanford Auto-Mounter. | |||
b |
|||
cThe Pearson correlation coefficient calculated for the average intensities resulting from division of the unmerged data into two parts, each containing half of the measurements selected at random for each unique reflection. | |||
dCoordinate error as implemented in PHENIX. |
TABLE 2 |
Thermodynamic Parameters for TAR Binding by TBP6.7 at 20° C. |
n | |||||||
Sample | KD | number | ΔH | −TΔS | ΔG | ΔΔGa b | |
TBP | nM | sites | kcal mol−1 | kcal mol−1 | kcal mol−1 | kcal mol−1 | Krel |
TBP6.7 | 2.5 ± 0.1 | 0.99 ± 0.02 | −25.0 ± 0.2 | 13.5 ± 0.2 | −11.6 ± 0.03 | n/a | |
P46A | 11.7 ± 2.5 | 0.97 ± 0.05 | −22.7 ± 0.2 | 12.1 ± 0.1 | −10.6 ± 0.1 | 1.0 | |
R47A | 1516 ± 163 | 0.96 ± 0.2 | −7.5 ± 1.1 | 0.3 ± 1.1 | −7.8 ± 0.1 | ~3.8c | |
R47K | 156 | 1.01 | −11.0 | 1.9 | −9.1 | 2.5 | |
Q48A | 5.5 ± 1.0 | 1.00 ± 0.01 | −22.6 ± 2.2 | 11.5 ± 2.1 | −11.1 ± 0.1 | 0.5 | |
Q48T | 3.6 ± 1.9 | 1.00 ± 0.04 | −25.7 ± 0.1 | 14.4 ± 0.2 | −11.4 ± 0.3 | 0.2 | |
R49A | 710 ± 205 | 0.91 ± 0.2 | −11.7 ± 3.2 | 3.4 ± 3.1 | −8.3 ± 0.2 | 3.3 | |
T50A | 11.4 ± XX | 1.00 ± XX | −20.7 ± XX | 10.1 ± XX | −10.6 ± |
1. | |
P51A | 10.8 ± 2.1 | 0.95 ± 0.05 | −23.1 ± 0.1 | 12.4 ± 0.0 | −10.7 ± 0.1 | 0.9 | |
R52A | 290 ± 57 | 1.00 ± 0.01 | −14.3 ± 0.3 | 5.5 ± 0.2 | −8.8 ± 0.08 | 2.8 | |
Q54A | 7.2 ± 2.4 | 1.05 ± 0.05 | −21.9 ± 2.0 | 10.9 ± 1.8 | −11.0 ± 0.2 | 0.6 | |
ΔC | 12.0 ± 3.0 | 1.01 ± 0.01 | −24.7 ± 2.7 | 14.1 ± 2.5 | −10.6 ± 0.2 | 1.0 | |
aThe difference of [ΔGmutant − ΔGTBP6.7]. | |||||||
bDefined as the ratio of [Mutant KD, App]/[WT KD, App] TBP6.7 at 20° C. | |||||||
cConsidered an estimate due to the low c-value associated with the measurement. |
- 1. https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html.
- 2. Bannwarth, S. & Gatignol, A. HIV-1 TAR RNA: the target of molecular interactions between the virus and its host.
Curr HIV Res 3, 61-71 (2005). - 3. Puglisi, J. D., Tan, R., Calnan, B. J., Frankel, A. D. & Williamson, J. R. Conformation of the TAR RNA-arginine complex by NMR spectroscopy. Science 257, 76-80 (1992).
- 4. Aboul-ela, F., Karn, J. & Varani, G. Structure of HIV-1 TAR RNA in the absence of ligands reveals a novel conformation of the trinucleotide bulge.
Nucleic Acids Res 24, 3974-3981 (1996). - 5. Huthoff, H. & Berkhout, B. Mutations in the TAR hairpin affect the equilibrium between alternative conformations of the HIV-1 leader RNA. Nucleic Acids Res 29, 2594-2600 (2001).
- 6. Harrich, D., Ulich, C. & Gaynor, R. B. A critical role for the TAR element in promoting efficient human
immunodeficiency virus type 1 reverse transcription. J Virol 70, 4017-4027 (1996). - Karn, J. & Stoltzfus, C. M. Transcriptional and posttranscriptional regulation of HIV-1 gene expression. Cold Spring
Harb Perspect Med 2, a006916 (2012). - 8. Ouellet, D. L., Plante, I., Landry, P., Barat, C., Janelle, M. E., Flamand, L., Tremblay, M. J. & Provost, P. Identification of functional microRNAs released through asymmetrical processing of HIV-1 TAR element. Nucleic Acids Res 36, 2353-2365 (2008).
- 9. Klase, Z., Winograd, R., Davis, J., Carpio, L., Hildreth, R., Heydarian, M., Fu, S., McCaffrey, T., Meiri, E., Ayash-Rashkovsky, M., Gilad, S., Bentwich, Z. & Kashanchi, F. HIV-1 TAR miRNA protects against apoptosis by altering cellular gene expression.
Retrovirology 6, 18 (2009). - 10. Klase, Z., Kale, P., Winograd, R., Gupta, M. V., Heydarian, M., Berro, R., McCaffrey, T. & Kashanchi, F. HIV-1 TAR element is processed by Dicer to yield a viral micro-RNA involved in chromatin remodeling of the viral LTR.
BMC Mol Biol 8, 63 (2007). - 11. Oubridge, C., Ito, N., Evans, P. R., Teo, C. H. & Nagai, K. Crystal structure at 1.92 A resolution of the RNA-binding domain of the U1A spliceosomal protein complexed with an RNA hairpin. Nature 372, 432-438 (1994).
- 12. Crawford, D. W., Blakeley, B. D., Chen, P. H., Sherpa, C., Le Grice, S. F., Laird-Offringa, I. A. & McNaughton, B. R. An Evolved RNA Recognition Motif That Suppresses HIV-1 Tat/TAR-Dependent Transcription.
ACS Chem Biol 11, 2206-2215 (2016). - 13. Richter, S., Ping, Y. H. & Rana, T. M. TAR RNA loop: a scaffold for the assembly of a regulatory switch in HIV replication. Proc Natl Acad Sci USA 99, 7928-7933 (2002).
- 14. Hamy, F., Felder, E. R., Heizmann, G., Lazdins, J., Aboul-ela, F., Varani, G., Karn, J. & Klimkait, T. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc Natl Acad Sci USA 94, 3548-3553 (1997).
- 15. Dingwall, C., Ernberg, I., Gait, M. J., Green, S. M., Heaphy, S., Karn, J., Lowe, A. D., Singh, M., Skinner, M. A. & Valerio, R.
Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro. Proc Natl Acad Sci USA 86, 6925-6929 (1989). - 16. Dingwall, C., Ernberg, I., Gait, M. J., Green, S. M., Heaphy, S., Karn, J., Lowe, A. D., Singh, M. & Skinner, M. A. HIV-1 tat protein stimulates transcription by binding to a U-rich bulge in the stem of the TAR RNA structure.
EMBO J 9, 4145-4153 (1990). - 17. Roy, S., Delling, U., Chen, C. H., Rosen, C. A. & Sonenberg, N. A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation.
Genes Dev 4, 1365-1373 (1990). - 18. Muesing, M. A., Smith, D. H. & Capon, D. J. Regulation of mRNA accumulation by a human immunodeficiency virus trans-activator protein.
Cell 48, 691-701 (1987). - 19. Jeang, K. T., Xiao, H. & Rich, E. A. Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J Biol Chem 274, 28837-28840 (1999).
- 20. Toohey, M. G. & Jones, K. A. In vitro formation of short RNA polymerase II transcripts that terminate within the HIV-1 and HIV-2 promoter-proximal downstream regions.
Genes Dev 3, 265-282 (1989). - 21. Selby, M. J., Bain, E. S., Luciw, P. A. & Peterlin, B. M. Structure, sequence, and position of the stem-loop in tar determine transcriptional elongation by tat through the HIV-1 long terminal repeat.
Genes Dev 3, 547-558 (1989). - 22. Verhoef, K., Koper, M. & Berkhout, B. Determination of the minimal amount of Tat activity required for human
immunodeficiency virus type 1 replication. Virology 237, 228-236 (1997). - 23. Sampey, G. C., Saifuddin, M., Schwab, A., Barclay, R., Punya, S., Chung, M. C., Hakami, R. M., Zadeh, M. A., Lepene, B., Klase, Z. A., El-Hage, N., Young, M., Iordanskiy, S. & Kashanchi, F. Exosomes from HIV-1-infected Cells Stimulate Production of Pro-inflammatory Cytokines through Trans-activating Response (TAR) RNA. J Biol Chem 291, 1251-1266 (2016).
- 24. Richter, S., Parolin, C., Gatto, B., Del Vecchio, C., Brocca-Cofano, E., Fravolini, A., Palu, G. & Palumbo, M. Inhibition of human
immunodeficiency virus type 1 tat-trans-activation-responsive region interaction by an antiviral quinolone derivative.Antimicrob Agents Chemother 48, 1895-1899 (2004). - 25. Parolin, C., Gatto, B., Del Vecchio, C., Pecere, T., Tramontano, E., Cecchetti, V., Fravolini, A., Masiero, S., Palumbo, M. & Palu, G. New anti-human
immunodeficiency virus type 1 6-aminoquinolones: mechanism of action. Antimicrob Agents Chemother 47, 889-896 (2003). - 26. Lind, K. E., Du, Z., Fujinaga, K., Peterlin, B. M. & James, T. L. Structure-based computational database screening, in vitro assay, and NMR assessment of compounds that target TAR RNA.
Chem Biol 9, 185-193 (2002). - 27. Stelzer, A. C., Frank, A. T., Kratz, J. D., Swanson, M. D., Gonzalez-Hernandez, M. J., Lee, J., Andricioaei, I., Markovitz, D. M. & Al-Hashimi, H. M. Discovery of selective bioactive small molecules by targeting an RNA dynamic ensemble.
Nat Chem Biol 7, 553-559 (2011). - 28. Hamasaki, K. & Ueno, A. Aminoglycoside antibiotics, neamine and its derivatives as potent inhibitors for the RNA-protein interactions derived from HIV-1 activators. Bioorg
Med Chem Lett 11, 591-594 (2001). - 29. Cabrera, C., Gutierrez, A., Blanco, J., Barretina, J., Litovchick, A., Lapidot, A., Evdokimov, A. G., Clotet, B. & Este, J. A. Anti-human immunodeficiency virus activity of novel aminoglycoside-arginine conjugates at early stages of infection. AIDS
Res Hum Retroviruses 16, 627-634 (2000). - 30. Litovchick, A., Evdokimov, A. G. & Lapidot, A. Arginine-aminoglycoside conjugates that bind to HIV transactivation responsive element RNA in vitro. FEBS Lett 445, 73-79 (1999).
- 31. Litovchick, A., Evdokimov, A. G. & Lapidot, A. Aminoglycoside-arginine conjugates that bind TAR RNA: synthesis, characterization, and antiviral activity. Biochemistry 39, 2838-2852 (2000).
- 32. Litovchick, A., Lapidot, A., Eisenstein, M., Kalinkovich, A. & Borkow, G. Neomycin B-arginine conjugate, a novel HIV-1 Tat antagonist: synthesis and anti-HIV activities.
Biochemistry 40, 15612-15623 (2001). - 33. Davidson, A., Leeper, T. C., Athanassiou, Z., Patora-Komisarska, K., Karn, J.,
- Robinson, J. A. & Varani, G. Simultaneous recognition of HIV-1 TAR RNA bulge and loop sequences by cyclic peptide mimics of Tat protein. Proc Natl Acad Sci USA 106, 11931-11936 (2009).
- 34. Davidson, A., Patora-Komisarska, K., Robinson, J. A. & Varani, G. Essential structural requirements for specific recognition of HIV TAR RNA by peptide mimetics of Tat protein. Nucleic Acids Res 39, 248-256 (2011).
- 35. Lalonde, M. S., Lobritz, M. A., Ratcliff, A., Chamanian, M., Athanassiou, Z., Tyagi, M., Wong, J., Robinson, J. A., Karn, J., Varani, G. & Arts, E. J. Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA.
PLoS Pathog 7, e1002038 (2011). - 36. Mousseau, G. & Valente, S. Strategies to Block HIV Transcription: Focus on Small Molecule Tat Inhibitors. Biology (Basel) 1, 668-697 (2012).
- 37. Velagapudi, S. P., Cameron, M. D., Haga, C. L., Rosenberg, L. H., Lafitte, M., Duckett, D. R., Phinney, D. G. & Disney, M. D. Design of a small molecule against an oncogenic noncoding RNA. Proc Natl Acad Sci USA 113, 5898-5903 (2016).
- 38. Costales, M. G., Rzuczek, S. G. & Disney, M. D. Comparison of small molecules and oligonucleotides that target a toxic, non-coding RNA. Bioorg Med Chem Lett 26, 2605-2609 (2016).
- 39. Bernat, V. & Disney, M. D. RNA Structures as Mediators of Neurological Diseases and as Drug Targets. Neuron 87, 28-46 (2015).
- 40. Rzuczek, S. G., Gao, Y., Tang, Z. Z., Thornton, C. A., Kodadek, T. & Disney, M. D. Features of modularly assembled compounds that impart bioactivity against an RNA target.
ACS Chem Biol 8, 2312-2321 (2013). - 41. Disney, M. D. Rational design of chemical genetic probes of RNA function and lead therapeutics targeting repeating transcripts.
Drug Discov Today 18, 1228-1236 (2013). - 42. Velagapudi, S. P. & Disney, M. D. Defining RNA motif-aminoglycoside interactions via two-dimensional combinatorial screening and structure-activity relationships through sequencing.
Bioorg Med Chem 21, 6132-6138 (2013). - 43. Childs-Disney, J. L., Parkesh, R., Nakamori, M., Thornton, C. A. & Disney, M. D. Rational design of bioactive, modularly assembled aminoglycosides targeting the RNA that causes
myotonic dystrophy type 1.ACS Chem Biol 7, 1984-1993 (2012). - 44. Childs-Disney, J. L., Hoskins, J., Rzuczek, S. G., Thornton, C. A. & Disney, M. D. Rationally designed small molecules targeting the RNA that causes
myotonic dystrophy type 1 are potently bioactive.ACS Chem Biol 7, 856-862 (2012). - 45. Childs-Disney, J. L., Tsitovich, P. B. & Disney, M. D. Using modularly assembled ligands to bind RNA internal loops separated by different distances.
Chembiochem 12, 2143-2146 (2011). - 46. Pushechnikov, A., Lee, M. M., Childs-Disney, J. L., Sobczak, K., French, J. M., Thornton, C. A. & Disney, M. D. Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic
muscular dystrophy type 1 andspinocerebellar ataxia type 3. J Am Chem Soc 131, 9767-9779 (2009). - 47. Lee, M. M., Pushechnikov, A. & Disney, M. D. Rational and modular design of potent ligands targeting the RNA that causes
myotonic dystrophy 2.ACS Chem Biol 4, 345-355 (2009). - 48. Blakeley, B. D. & McNaughton, B. R. Synthetic RNA recognition motifs that selectively recognize HIV-1 trans-activation response element hairpin RNA.
ACS Chem Biol 9, 1320-1329 (2014). - 49. Churcher, M. J., Lamont, C., Hamy, F., Dingwall, C., Green, S. M., Lowe, A. D., Butler, J. G., Gait, M. J. & Karn, J. High affinity binding of TAR RNA by the human immunodeficiency virus type-1 tat protein requires base-pairs in the RNA stem and amino acid residues flanking the basic region. J Mol Biol 230, 90-110 (1993).
- 50. Delling, U., Reid, L. S., Barnett, R. W., Ma, M. Y., Climie, S., Sumner-Smith, M. & Sonenberg, N. Conserved nucleotides in the TAR RNA stem of human
immunodeficiency virus type 1 are critical for Tat binding and trans activation: model for TAR RNA tertiary structure. J Virol 66, 3018-3025 (1992). - 51. Weeks, K. M. & Crothers, D. M. RNA recognition by Tat-derived peptides: interaction in the major groove? Cell 66, 577-588 (1991).
- 52. Calnan, B. J., Tidor, B., Biancalana, S., Hudson, D. & Frankel, A. D. Arginine-mediated RNA recognition: the arginine fork. Science 252, 1167-1171 (1991).
- 53. Hamy, F., Asseline, U., Grasby, J., Iwai, S., Pritchard, C., Slim, G., Butler, P. J., Karn, J. & Gait, M. J. Hydrogen-bonding contacts in the major groove are required for human immunodeficiency virus type-1 tat protein recognition of TAR RNA. J Mol Biol 230, 111-123 (1993).
- 54. Pritchard, C. E., Grasby, J. A., Hamy, F., Zacharek, A. M., Singh, M., Karn, J. & Gait, M. J. Methylphosphonate mapping of phosphate contacts critical for RNA recognition by the human immunodeficiency virus tat and rev proteins.
Nucleic Acids Res 22, 2592-2600 (1994). - 55. Tao, J. & Frankel, A. D. Specific binding of arginine to TAR RNA. Proc Natl Acad Sci USA 89, 2723-2726 (1992).
- 56. Sumner-Smith, M., Roy, S., Barnett, R., Reid, L. S., Kuperman, R., Delling, U. & Sonenberg, N. Critical chemical features in trans-acting-responsive RNA are required for interaction with human
immunodeficiency virus type 1 Tat protein. J Virol 65, 5196-5202 (1991). - 57. Aboul-ela, F., Karn, J. & Varani, G. The structure of the human immunodeficiency virus type-1 TAR RNA reveals principles of RNA recognition by Tat protein. J Mol Biol 253, 313-332 (1995).
- 58. Borkar, A. N., Bardaro, M. F., Jr., Camilloni, C., Aprile, F. A., Varani, G. & Vendruscolo, M. Structure of a low-population binding intermediate in protein-RNA recognition. Proc Natl Acad Sci USA 113, 7171-7176 (2016).
- 59. Fu, A., Tang, R., Hardie, J., Farkas, M. E. & Rotello, V. M. Promises and pitfalls of intracellular delivery of proteins.
Bioconjug Chem 25, 1602-1608 (2014). - 60. Frokjaer, S. & Otzen, D. E. Protein drug stability: a formulation challenge. Nat
Rev Drug Discov 4, 298-306 (2005). - 61. Patel, I. H., Zhang, X., Nieforth, K., Salgo, M. & Buss, N. Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet 44, 175-186 (2005).
- 62. Fosgerau, K. & Hoffmann, T. Peptide therapeutics: current status and future directions.
Drug Discov Today 20, 122-128 (2015). - 63. Howell, S. M., Fiacco, S. V., Takahashi, T. T., Jalali-Yazdi, F., Millward, S. W., Hu, B., Wang, P. & Roberts, R. W. Serum stable natural peptides designed by mRNA display.
Sci Rep 4, 6008 (2014). - 64. Adessi, C., Frossard, M. J., Boissard, C., Fraga, S., Bieler, S., Ruckle, T., Vilbois, F., Robinson, S. M., Mutter, M., Banks, W. A. & Soto, C. Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease. J Biol Chem 278, 13905-13911 (2003).
- 65. Bockus, A. T., McEwen, C. M. & Lokey, R. S. Form and function in cyclic peptide natural products: a pharmacokinetic perspective. Curr
Top Med Chem 13, 821-836 (2013). - 66. Sieber, S. A. & Marahiel, M. A. Learning from nature's drug factories: nonribosomal synthesis of macrocyclic peptides. J Bacteriol 185, 7036-7043 (2003).
- 67. Watanabe, K., Hotta, K., Praseuth, A. P., Koketsu, K., Migita, A., Boddy, C. N., Wang, C. C., Oguri, H. & Oikawa, H. Total biosynthesis of antitumor nonribosomal peptides in Escherichia coli.
Nat Chem Biol 2, 423-428 (2006). - 68. Blakeley, B. D., Shattuck, J., Coates, M. B., Tran, E., Laird-Offringa, I. A. & McNaughton, B. R. Analysis of protein-RNA complexes involving a RNA recognition motif engineered to bind hairpins with seven- and eight-nucleotide loops.
Biochemistry 52, 4745-4747 (2013). - 69. Chapman, A. M. & McNaughton, B. R. Scratching the Surface: Resurfacing Proteins to Endow New Properties and Function.
Cell Chem Biol 23, 543-553 (2016). - 70. Bruce, V. J., Lopez-Islas, M. & McNaughton, B. R. Resurfaced cell-penetrating nanobodies: A potentially general scaffold for intracellularly targeted protein discovery.
Protein Sci 25, 1129-1137 (2016). - 71. Gray, M. A., Tao, R. N., DePorter, S. M., Spiegel, D. A. & McNaughton, B. R. A Nanobody Activation Immunotherapeutic that Selectively Destroys HER2-Positive Breast Cancer Cells.
Chembiochem 17, 155-158 (2016). - 72. Chapman, A. M. & McNaughton, B. R. Synthetic Proteins Potently and Selectively Bind the Oncoprotein Gankyrin, Modulate Its Interaction with S6 ATPase, and Suppress Gankyrin/MDM2-Dependent Ubiquitination of p53.
ACS Chem Biol 10, 1880-1886 (2015). - 73. Walker, S. N., Tennyson, R. L., Chapman, A. M., Kennan, A. J. & McNaughton, B. R. GLUE that sticks to HIV: a helix-grafted GLUE protein that selectively binds the HIV gp41 N-terminal helical region.
Chembiochem 16, 219-222 (2015). - 74. Chapman, A. M. & McNaughton, B. R. Resurfaced shape complementary proteins that selectively bind the oncoprotein gankyrin.
ACS Chem Biol 9, 2223-2228 (2014). - 75. McNaughton, B. R. & Miller, B. L. Resin-bound dynamic combinatorial chemistry.
Org Lett 8, 1803-1806 (2006). - 76. McNaughton, B. R., Gareiss, P. C. & Miller, B. L. Identification of a selective small-molecule ligand for HIV-1 frameshift-inducing stem-loop RNA from an 11,325 member resin bound dynamic combinatorial library. J Am Chem Soc 129, 11306-11307 (2007).
- 77. Gareiss, P. C., Sobczak, K., McNaughton, B. R., Palde, P. B., Thornton, C. A. & Miller, B. L. Dynamic combinatorial selection of molecules capable of inhibiting the (CUG) repeat RNA-MBNL1 interaction in vitro: discovery of lead compounds targeting myotonic dystrophy (DM1). J
Am Chem Soc 130, 16254-16261 (2008). - 78. McNaughton, B. R., Cronican, J. J., Thompson, D. B. & Liu, D. R. Mammalian cell penetration, siRNA transfection, and DNA transfection by supercharged proteins. Proc Natl Acad Sci USA 106, 6111-6116 (2009).
- 79. Cronican, J. J., Thompson, D. B., Beier, K. T., McNaughton, B. R., Cepko, C. L. & Liu, D. R. Potent delivery of functional proteins into Mammalian cells in vitro and in vivo using a supercharged protein.
ACS Chem Biol 5, 747-752 (2010). - 80. DePorter, S. M., Lui, I., Mohan, U. & McNaughton, B. R. A protein transduction domain with cell uptake and selectivity profiles that are controlled by multivalency effects.
Chem Biol 20, 434-444 (2013). - 81. DePorter, S. M., Lui, I., Bruce, V. J., Gray, M. A., Lopez-Islas, M. & McNaughton, B. R. Mutagenesis modulates the uptake efficiency, cell-selectivity, and functional enzyme delivery of a protein transduction domain.
Mol Biosyst 10, 18-23 (2014). - 82. DePorter, S. M. & McNaughton, B. R. Engineered M13 bacteriophage nanocarriers for intracellular delivery of exogenous proteins to human prostate cancer cells.
Bioconjug Chem 25, 1620-1625 (2014). - 83. Jenkins, J. L., Krucinska, J., McCarty, R. M., Bandarian, V. & Wedekind, J. E. Comparison of a preQ1 riboswitch aptamer in metabolite-bound and free states with implications for gene regulation. J Biol Chem 286, 24626-24637 (2011).
- 84. Liberman, J. A., Suddala, K. C., Aytenfisu, A., Chan, D., Belashov, I. A., Salim, M., Mathews, D. H., Spitale, R. C., Walter, N. G. & Wedekind, J. E. Structural analysis of a class III preQ1 riboswitch reveals an aptamer distant from a ribosome-binding site regulated by fast dynamics. Proc Natl Acad Sci USA 112, E3485-3494 (2015).
- 85. Spitale, R. C., Torelli, A. T., Krucinska, J., Bandarian, V. & Wedekind, J. E. The structural basis for recognition of the PreQ0 metabolite by an unusually small riboswitch aptamer domain. J Biol Chem 284, 11012-11016 (2009).
- 86. Suddala, K. C., Rinaldi, A. J., Feng, J., Mustoe, A. M., Eichhorn, C. D., Liberman, J. A., Wedekind, J. E., Al-Hashimi, H. M., Brooks, C. L., 3rd & Walter, N. G. Single transcriptional and translational preQ1 riboswitches adopt similar pre-folded ensembles that follow distinct folding pathways into the same ligand-bound structure.
Nucleic Acids Res 41, 10462-10475 (2013). - 87. Jamburuthugoda, V. K., Guo, D., Wedekind, J. E. & Kim, B. Kinetic evidence for interaction of human
immunodeficiency virus type 1 reverse transcriptase with the 3′-OH of the incoming dTTP substrate. Biochemistry 44, 10635-10643 (2005). - 88. Jamburuthugoda, V. K., Santos-Velazquez, J. M., Skasko, M., Operario, D. J., Purohit, V., Chugh, P., Szymanski, E. A., Wedekind, J. E., Bambara, R. A. & Kim, B. Reduced dNTP binding affinity of 3TC-resistant M184I HIV-1 reverse transcriptase variants responsible for viral infection failure in macrophage. J Biol Chem 283, 9206-9216 (2008).
- 89. Lippa, G. M. in Biochemistry and Biophysics, Vol. Ph.D. 240 (University of Rochester School of Medicine and Dentistry, 2013).
- 90. Lippa, G. M., Liberman, J. A., Jenkins, J. L., Krucinska, J., Salim, M. & Wedekind, J. E. Crystallographic analysis of small ribozymes and riboswitches. Methods Mol Biol 848, 159-184 (2012).
- 91. Wedekind, J. E., Gillilan, R., Janda, A., Krucinska, J., Salter, J. D., Bennett, R. P., Raina, J. & Smith, H. C. Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular mass ribonucleoprotein particles from dimeric subunits. J Biol Chem 281, 38122-38126 (2006).
- 92. Xie, K., Sowden, M. P., Dance, G. S., Torelli, A. T., Smith, H. C. & Wedekind, J. E. The structure of a yeast RNA-editing deaminase provides insight into the fold and function of activation-induced deaminase and APOBEC-1. Proc Natl Acad Sci USA 101, 8114-8119 (2004).
- 93. Bennett, R. P., Salter, J. D., Liu, X., Wedekind, J. E. & Smith, H. C. APOBEC3G subunits self-associate via the C-terminal deaminase domain. J Biol Chem 283, 33329-33336 (2008).
- 94. Wang, W., Maucuer, A., Gupta, A., Manceau, V., Thickman, K. R., Bauer, W. J., Kennedy, S. D., Wedekind, J. E., Green, M. R. & Kielkopf, C. L. Structure of phosphorylated SF1 bound to U2AF(6)(5) in an essential splicing factor complex.
Structure 21, 197-208 (2013). - 95. Dutton, G. HIV Researchers Seek a Potential Cure. Genetic Engineering &
Biotechnology News 33, 4997 (2013). - 96. Majmudar, N. OyaGen blazing path toward anti-AIDS drug. Rochester Democrat and Chronicle, D106 (2005).
- 97. Salter, J. D., Morales, G. A. & Smith, H. C. Structural insights for HIV-1 therapeutic strategies targeting Vif. Trends Biochem Sci 39, 373-380 (2014).
- 98. Pilon, J. L., Clausen, D. J., Hansen, R. J., Lunghofer, P. J., Charles, B., Rose, B. J., Thamm, D. H., Gustafson, D. L., Bradner, J. E. & Williams, R. M. Comparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostere. Cancer Chemother Pharmacol 75, 671-682 (2015).
- 99. Paoloni, M. C., Mazcko, C., Fox, E., Fan, T., Lana, S., Kisseberth, W., Vail, D. M., Nuckolls, K., Osborne, T., Yalkowsy, S., Gustafson, D., Yu, Y., Cao, L. & Khanna, C. Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs. PLoS One 5, e11013 (2010).
- 100. Hudachek, S. F. & Gustafson, D. L. Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans.
J Pharmacokinet Pharmacodyn 40, 157-176 (2013). - 101. Thomas, R. S., Conolly, R. B., Gustafson, D. L., Long, M. E., Benjamin, S. A. & Yang, R. S. A physiologically based pharmacodynamic analysis of hepatic foci within a medium-term liver bioassay using pentachlorobenzene as a promoter and diethylnitrosamine as an initiator. Toxicol Appl Pharmacol 166, 128-137 (2000).
- 102. Puglisi, J. D., Chen, L., Blanchard, S. & Frankel, A. D. Solution structure of a bovine immunodeficiency virus Tat-TAR peptide-RNA complex. Science 270, 1200-1203 (1995).
- 103. Wilkinson, K. A., Merino, E. J. & Weeks, K. M. Selective 2′-hydroxyl acylation analyzed by primer extension (SHAPE): quantitative RNA structure analysis at single nucleotide resolution.
Nat Protoc 1, 1610-1616 (2006). - 104. Berkhout, B. & van Wamel, J. L. The leader of the HIV-1 RNA genome forms a compactly folded tertiary structure.
RNA 6, 282-295 (2000). - 105. Clever, J., Sassetti, C. & Parslow, T. G. RNA secondary structure and binding sites for gag gene products in the 5′ packaging signal of human
immunodeficiency virus type 1. J Virol 69, 2101-2109 (1995). - 106. Keane, S. C., Heng, X., Lu, K., Kharytonchyk, S., Ramakrishnan, V., Carter, G., Barton, S., Hosic, A., Florwick, A., Santos, J., Bolden, N. C., McCowin, S., Case, D. A., Johnson, B. A., Salemi, M., Telesnitsky, A. & Summers, M. F. RNA structure. Structure of the HIV-1 RNA packaging signal. Science 348, 917-921 (2015).
- 107. Olsen, G. L., Edwards, T. E., Deka, P., Varani, G., Sigurdsson, S. T. & Drobny, G. P. Monitoring tat peptide binding to TAR RNA by solid-state 31P-19F REDOR NMR.
Nucleic Acids Res 33, 3447-3454 (2005). - 108. Bandziulis, R. J., Swanson, M. S. & Dreyfuss, G. RNA-binding proteins as developmental regulators.
Genes Dev 3, 431-437 (1989). - 109. Query, C. C., Bentley, R. C. & Keene, J. D. A common RNA recognition motif identified within a defined U1 RNA binding domain of the 70K U1 snRNP protein. Cell 57, 89-101 (1989).
- 110. Critchley, A. D., Haneef, I., Cousens, D. J. & Stockley, P. G. Modeling and solution structure probing of the HIV-1 TAR stem-loop.
J Mol Graph 11, 92-97, 124 (1993). - 111. Kulinski, T., Olejniczak, M., Huthoff, H., Bielecki, L., Pachulska-Wieczorek, K., Das, A. T., Berkhout, B. & Adam iak, R. W. The apical loop of the HIV-1 TAR RNA hairpin is stabilized by a cross-loop base pair. J Biol Chem 278, 38892-38901 (2003).
- 112. Richter, S., Cao, H. & Rana, T. M. Specific HIV-1 TAR RNA loop sequence and functional groups are required for human cyclin T1-Tat-TAR ternary complex formation.
Biochemistry 41, 6391-6397 (2002). - 113. Liberman, J. A., Bogue, J. T., Jenkins, J. L., Salim, M. & Wedekind, J. E. ITC analysis of ligand binding to preQ(1) riboswitches. Methods Enzymol 549, 435-450 (2014).
- 114. Hay, R. T. SUMO: a history of modification.
Mol Cell 18, 1-12 (2005). - 115. Wedekind, J. E. & McKay, D. B. Purification, crystallization, and X-ray diffraction analysis of small ribozymes. Methods Enzymol 317, 149-168 (2000).
- 116. Liberman, J. A., Salim, M., Krucinska, J. & Wedekind, J. E. Structure of a class II preQ1 riboswitch reveals ligand recognition by a new fold.
Nat Chem Biol 9, 353-355 (2013). - 117. Myszka, D. G. Kinetic analysis of macromolecular interactions using surface plasmon resonance biosensors.
Curr Opin Biotechnol 8, 50-57 (1997). - 118. Rupert, P. B., Xiao, H. & Ferre-D'Amare, A. R. U1A RNA-binding domain at 1.8 A resolution. Acta Crystallogr D Biol Crystallogr 59, 1521-1524 (2003).
- 119. McPherson, A. Introduction to protein crystallization. Methods 34, 254-265 (2004).
- 120. Doudna, J. A., Grosshans, C., Gooding, A. & Kundrot, C. E. Crystallization of ribozymes and small RNA motifs by a sparse matrix approach. Proc Natl Acad Sci USA 90, 7829-7833 (1993).
- 121. Gilliland, G. L., Tung, M., Blakeslee, D. M. & Ladner, J. E. Biological Macromolecule Crystallization Database, Version 3.0: new features, data and the NASA archive for protein crystal growth data. Acta Crystallogr
D Biol Crystallogr 50, 408-413 (1994). - 122. Ke, A. & Doudna, J. A. Crystallization of RNA and RNA-protein complexes. Methods 34, 408-414 (2004).
- 123. Scott, W. G., Finch, J. T., Grenfell, R., Fogg, J., Smith, T., Gait, M. J. & Klug, A. Rapid crystallization of chemically synthesized hammerhead RNAs using a double screening procedure. J Mol Biol 250, 327-332 (1995).
- 124. Kraft, P., Bergamaschi, A., Broennimann, C., Dinapoli, R., Eikenberry, E. F., Henrich, B., Johnson, I., Mozzanica, A., Schleputz, C. M., Willmott, P. R. & Schmitt, B. Performance of single-photon-counting PILATUS detector modules.
J Synchrotron Radiat 16, 368-375 (2009). - 125. Kabsch, W. Xds. Acta Crystallogr D Biol Crystallogr 66, 125-132 (2010).
- 126. Mueller, M., Wang, M. & Schulze-Briese, C. Optimal fine phi-slicing for single-photon-counting pixel detectors. Acta Crystallogr D Biol Crystallogr 68, 42-56 (2012).
- 127. Pflugrath, J. W. The finer things in X-ray diffraction data collection. Acta Crystallogr
D Biol Crystallogr 55, 1718-1725 (1999). - 128. Gonzalez, A., Moorhead, P., McPhillips, S. E., Song, J., Sharp, K., Taylor, J. R., Adams, P. D., Sauter, N. K. & Soltis, S. M. Web-Ice: integrated data collection and analysis for macromolecular crystallography. Journal of
Applied Crystallography 41, 176-184 (2008). - 129. Murray, J. W., Garman, E. F. & Ravelli, R. B. G. X-ray absorption by macromolecular crystals: the effects of wavelength and crystal composition on absorbed dose. Journal of Applied Crystallography 37, 513-522 (2004).
- 130. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J. Phaser crystallographic software.
J Appl Crystallogr 40, 658-674 (2007). - 131. Wedekind, J. E., Frey, P. A. & Rayment, I. Three-dimensional structure of galactose-1-phosphate uridylyltransferase from Escherichia coli at 1.8 A resolution. Biochemistry 34, 11049-11061 (1995).
- 132. Wedekind, J. E. & McKay, D. B. Crystal structure of a lead-dependent ribozyme revealing metal binding sites relevant to catalysis.
Nat Struct Biol 6, 261-268 (1999). - 133. Goodman, J. L., Wang, S., Alam, S., Ruzicka, F. J., Frey, P. A. & Wedekind, J. E. Ornithine cyclodeaminase: structure, mechanism of action, and implications for the mu-crystallin family. Biochemistry 43, 13883-13891 (2004).
- 134. Ferre-D'Amare, A. R. Use of the spliceosomal protein U1A to facilitate crystallization and structure determination of complex RNAs.
Methods 52, 159-167 (2010). - 135. Bruno, B. J., Miller, G. D. & Lim, C. S. Basics and recent advances in peptide and protein drug delivery.
Ther Deliv 4, 1443-1467 (2013). - 136. Amblard, M., Fehrentz, J. A., Martinez, J. & Subra, G. Methods and protocols of modern solid phase Peptide synthesis.
Mol Biotechnol 33, 239-254 (2006). - 137. Palomo, J. M. Solid-phase peptide synthesis: an overview focused on the preparation of biologically relevant peptides. Rsc Advances 4, 32658-32672 (2014).
- 138. Chatterjee, J., Laufer, B. & Kessler, H. Synthesis of N-methylated cyclic peptides.
Nature Protocols 7, 432-444 (2012). - 139. Mishra, J. K., Zhang, C., Spokoyny, A. M., Pentelute, B. L. & Snyder, S. E. A Perfluoroaryl-Cysteine SNAr Chemistry Approach towards F-18 labeling of Bioactive Peptides. Journal of Labelled Compounds & Radiopharmaceuticals 58, S265-S265 (2015).
- 140. Spokoyny, A. M., Zou, Y. K., Ling, J. J., Yu, H. T., Lin, Y. S. & Pentelute, B. L. A Perfluoroaryl-Cysteine SNAr Chemistry Approach to Unprotected Peptide Stapling. Journal of the American Chemical Society 135, 5946-5949 (2013).
- 141. Rink, R., Arkema-Meter, A., Baudoin, I., Post, E., Kuipers, A., Nelemans, S. A., Akanbi, M. H. & Moll, G. N. To protect peptide pharmaceuticals against peptidases. J Pharmacol Toxicol Methods 61, 210-218 (2010).
- 142. Chapman, A. M., Rogers, B. E. & McNaughton, B. R. Characterization of the binding interaction between the oncoprotein gankyrin and a grafted S6 ATPase. Biochemistry 53, 6857-6859 (2014).
- 143. Bird, G. H., Mazzola, E., Opoku-Nsiah, K., Lammert, M. A., Godes, M., Neuberg, D. S. & Walensky, L. D. Biophysical determinants for cellular uptake of hydrocarbon-stapled peptide helices. Nat Chem Biol (2016).
- 144. Maianti, J. P., McFedries, A., Foda, Z. H., Kleiner, R. E., Du, X. Q., Leissring, M. A., Tang, W. J., Charron, M. J., Seeliger, M. A., Saghatelian, A. & Liu, D. R. Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones. Nature 511, 94-98 (2014).
- 145. Hilimire, T. A., Bennett, R. P., Stewart, R. A., Garcia-Miranda, P., Blume, A., Becker, J., Sherer, N., Helms, E. D., Butcher, S. E., Smith, H. C. & Miller, B. L. N-Methylation as a Strategy for Enhancing the Affinity and Selectivity of RNA-binding Peptides: Application to the HIV-1 Frameshift-Stimulating RNA.
ACS Chem Biol 11, 88-94 (2016). - 146. Qian, Z., Liu, T., Liu, Y. Y., Briesewitz, R., Barrios, A. M., Jhiang, S. M. & Pei, D. Efficient delivery of cyclic peptides into mammalian cells with short sequence motifs.
ACS Chem Biol 8, 423-431 (2013). - 147. Oh, D., Sun, J., Nasrolahi Shirazi, A., LaPlante, K. L., Rowley, D. C. & Parang, K. Antibacterial activities of amphiphilic cyclic cell-penetrating peptides against multidrug-resistant pathogens.
Mol Pharm 11, 3528-3536 (2014). - 148. Yang, J., Tsutsumi, H., Furuta, T., Sakurai, M. & Mihara, H. Interaction of amphiphilic alpha-helical cell-penetrating peptides with heparan sulfate.
Org Biomol Chem 12, 4673-4681 (2014). - 149. Sardan, M., Kilinc, M., Genc, R., Tekinay, A. B. & Guler, M. O. Cell penetrating peptide amphiphile integrated liposomal systems for enhanced delivery of anticancer drugs to tumor cells. Faraday Discuss 166, 269-283 (2013).
- 150. Eiriksdottir, E., Konate, K., Langel, U., Divita, G. & Deshayes, S. Secondary structure of cell-penetrating peptides controls membrane interaction and insertion. Biochim Biophys Acta 1798, 1119-1128 (2010).
- 151. Liao, X. L., Rabideau, A. E. & Pentelute, B. L. Delivery of Antibody Mimics into Mammalian Cells via Anthrax Toxin Protective Antigen.
Chembiochem 15, 2458-2466 (2014). - 152. Alam, S., Grum-Tokars, V., Krucinska, J., Kundracik, M. L. & Wedekind, J. E. Conformational heterogeneity at position U37 of an all-RNA hairpin ribozyme with implications for metal binding and the catalytic structure of the S-turn. Biochemistry 44, 14396-14408 (2005).
- 153. Salter, J., Krucinska, J., Alam, S., Grum-Tokars, V. & Wedekind, J. E. Water in the active site of an all-RNA hairpin ribozyme and effects of Gua8 base variants on the geometry of phosphoryl transfer. Biochemistry 45, 686-700 (2006).
- 154. Wedekind, J. E. & McKay, D. B. Crystal structure of the leadzyme at 1.8 A resolution: metal ion binding and the implications for catalytic mechanism and allo site ion regulation. Biochemistry 42, 9554-9563 (2003).
- 155. Li, M., Tao, Y., Shu, Y. L., LaRochelle, J. R., Steinauer, A., Thompson, D., Schepartz, A., Chen, Z. Y. & Liu, D. R. Discovery and Characterization of a Peptide That Enhances Endosomal Escape of Delivered Proteins in Vitro and in Vivo. Journal of the American Chemical Society 137, 14084-14093 (2015).
- 156. Platt, E. J., Wehrly, K., Kuhmann, S. E., Chesebro, B. & Kabat, D. Effects of CCRS and CD4 cell surface concentrations on infections by macrophagetropic isolates of human
immunodeficiency virus type 1. J Virol 72, 2855-2864 (1998). - 157. Shan, L., Rabi, S. A., Laird, G. M., Eisele, E. E., Zhang, H., Margolick, J. B. & Siliciano, R. F. A novel PCR assay for quantification of HIV-1 RNA. J Virol 87, 6521-6525 (2013).
Claims (34)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/805,933 US10538556B2 (en) | 2016-11-07 | 2017-11-07 | Anti-HIV peptides |
US16/723,164 US11186614B2 (en) | 2016-11-07 | 2019-12-20 | Anti-HIV peptides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662418529P | 2016-11-07 | 2016-11-07 | |
US15/805,933 US10538556B2 (en) | 2016-11-07 | 2017-11-07 | Anti-HIV peptides |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/723,164 Division US11186614B2 (en) | 2016-11-07 | 2019-12-20 | Anti-HIV peptides |
Publications (2)
Publication Number | Publication Date |
---|---|
US20180127468A1 US20180127468A1 (en) | 2018-05-10 |
US10538556B2 true US10538556B2 (en) | 2020-01-21 |
Family
ID=60409440
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/805,933 Expired - Fee Related US10538556B2 (en) | 2016-11-07 | 2017-11-07 | Anti-HIV peptides |
US16/723,164 Active US11186614B2 (en) | 2016-11-07 | 2019-12-20 | Anti-HIV peptides |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/723,164 Active US11186614B2 (en) | 2016-11-07 | 2019-12-20 | Anti-HIV peptides |
Country Status (2)
Country | Link |
---|---|
US (2) | US10538556B2 (en) |
WO (1) | WO2018085836A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111777668B (en) * | 2020-07-28 | 2022-02-25 | 安徽工程大学 | Marine cyclopeptide Samoamide A-based modified polypeptide, synthetic method and application |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5646120A (en) | 1990-10-24 | 1997-07-08 | Allelix Biopharmaceuticals, Inc. | Peptide-based inhibitors of HIV replication |
FR2792204A1 (en) | 1999-04-13 | 2000-10-20 | Centre Nat Rech Scient | Vaccine against human immunodeficiency virus-1 and acquired immunodeficiency syndrome, comprising defective Tat protein or fragment which can attach to TAR but not cause transactivation |
US8889394B2 (en) * | 2009-09-07 | 2014-11-18 | Empire Technology Development Llc | Multiple domain proteins |
US20160282347A1 (en) * | 2013-11-06 | 2016-09-29 | Bard1Ag Sa | Lung cancer diagnosis |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4547489A (en) | 1984-06-11 | 1985-10-15 | Ortho Pharmaceutical Corporation | Conformationally restricted thymopentin-like compounds |
WO1990001940A1 (en) | 1988-08-18 | 1990-03-08 | California Biotechnology Inc. | Atrial natriuretic peptide clearance inhibitors |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
GB9814527D0 (en) | 1998-07-03 | 1998-09-02 | Cyclacel Ltd | Delivery system |
GB201409538D0 (en) | 2014-05-29 | 2014-07-16 | Univ The Durham | Cyclising peptides |
-
2017
- 2017-11-07 US US15/805,933 patent/US10538556B2/en not_active Expired - Fee Related
- 2017-11-07 WO PCT/US2017/060400 patent/WO2018085836A1/en active Application Filing
-
2019
- 2019-12-20 US US16/723,164 patent/US11186614B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5646120A (en) | 1990-10-24 | 1997-07-08 | Allelix Biopharmaceuticals, Inc. | Peptide-based inhibitors of HIV replication |
FR2792204A1 (en) | 1999-04-13 | 2000-10-20 | Centre Nat Rech Scient | Vaccine against human immunodeficiency virus-1 and acquired immunodeficiency syndrome, comprising defective Tat protein or fragment which can attach to TAR but not cause transactivation |
US8889394B2 (en) * | 2009-09-07 | 2014-11-18 | Empire Technology Development Llc | Multiple domain proteins |
US20160282347A1 (en) * | 2013-11-06 | 2016-09-29 | Bard1Ag Sa | Lung cancer diagnosis |
Non-Patent Citations (7)
Title |
---|
Adessi et al, "Coverting a Peptide into a Drug: Strategies to Improve Stability and Bioavailability," Current Medicinal Chemistry, 2002, 9: 963-978. * |
Crawford DW et al. An Evolved RNA Recognition Motif that Suppresses HIV-1 Tat/TAR-Dependent Transcription. ACS Chem Biol. Aug. 19, 2016;11(8):2206-2215. |
Davidson A et al. Simultaneous recognition of HIV-1 TAR RNA bulge and loop sequences by cyclic peptide mimics of Tat protein. Proceedings National Academy of Sciences PNAS. Jul. 21, 2009;106(29):11931-11936. |
Fu J et al. Design-Based Peptidomimetic Ligand Discovery to Target HIV TAR RNA Using Comparative Analysis of Different Docking Methods. Current HIV Research. 2016;14(6):476-483. |
International Search Report and Written Opinion, PCT/US2017/060400, dated Feb. 8, 2018. |
Li CH et al. The interactions and recognition of cyclic peptide mimetics of Tat with HIV-1 TAR RNA: a molecular dynamics simulation study. Journal of Biomolecular Structure and Dynamics. Mar. 1, 2013;31(3):276-287. |
Xie B et al. Selection of TAR RNA-Binding Chameleon Peptides by Using a Retroviral Replication System. Journal of Virology. Feb. 2004;78(3):1456-1463. |
Also Published As
Publication number | Publication date |
---|---|
WO2018085836A1 (en) | 2018-05-11 |
US11186614B2 (en) | 2021-11-30 |
US20180127468A1 (en) | 2018-05-10 |
US20200115418A1 (en) | 2020-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Im et al. | Crystallographic and functional analysis of the ESCRT-I/HIV-1 Gag PTAP interaction | |
EP1989220B1 (en) | Hiv fusion inhibitor peptides with improved biological properties | |
JP6265583B2 (en) | Method for producing bioactive alpha beta peptide | |
JP2003514765A (en) | Novel transducing molecules and methods of use | |
JP2010505831A (en) | Stabilized, therapeutic small helical antiviral peptide | |
JP2010180217A (en) | Inhibitor of hiv membrane fusion | |
Schneider et al. | Development of HIV fusion inhibitors | |
Chen et al. | TSG101: a novel anti-HIV-1 drug target | |
JP7057822B2 (en) | Lipopeptides for strongly inhibiting HIV, derivatives thereof, pharmaceutical compositions thereof and their use | |
US11186614B2 (en) | Anti-HIV peptides | |
US8937154B2 (en) | Stabilized therapeutic small helical antiviral peptides | |
EP2097090B1 (en) | Peptide and treatment for hiv-1 infection | |
Kaushik-Basu et al. | Peptide inhibition of HIV-1: current status and future potential | |
WO2007068163A1 (en) | Hiv fusion inhibitor peptides and use thereof | |
WO2018141089A1 (en) | Hiv inhibiting broad-spectrum lipopeptide, derivatives thereof, pharmaceutical compositions thereof, and use thereof | |
Cai et al. | Peptides and peptidomimetics as tools to probe protein-protein interactions–disruption of HIV-1 gp41 fusion core and fusion inhibitor design | |
Liang et al. | Research Strategy for Short-Peptide Fusion Inhibitors Based on 6-HB Core Structure against HIV-1: A Review | |
US20160310567A1 (en) | Compositions for inhibiting viral replication and methods of use and production thereof | |
WO2005068492A2 (en) | Peptide inhibitors of retroviral integrase useful for the treatment of retroviral infection | |
OA19487A (en) | Potent HIV inhibiting lipopeptide, derivative thereof, pharmaceutical composition thereof and use thereof. | |
CA2766417A1 (en) | Stabilized therapeutic small helical antiviral peptides | |
AU2012200580A1 (en) | Stabilized therapeutic small helical antiviral peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
AS | Assignment |
Owner name: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION, COLORADO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MCNAUGHTON, BRIAN R.;CRAWFORD, DAVID W.;SIGNING DATES FROM 20180125 TO 20180126;REEL/FRAME:046258/0380 Owner name: UNIVERSITY OF ROCHESTER, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WEDEKIND, JOSEPH E.;REEL/FRAME:046472/0673 Effective date: 20171229 Owner name: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION, COL Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MCNAUGHTON, BRIAN R.;CRAWFORD, DAVID W.;SIGNING DATES FROM 20180125 TO 20180126;REEL/FRAME:046258/0380 |
|
AS | Assignment |
Owner name: UNIVERSITY OF ROCHESTER, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BELASHOV, IVAN A.;REEL/FRAME:046958/0890 Effective date: 20180822 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
FEPP | Fee payment procedure |
Free format text: PETITION RELATED TO MAINTENANCE FEES GRANTED (ORIGINAL EVENT CODE: PTGR); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT, MARYLAND Free format text: CONFIRMATORY LICENSE;ASSIGNOR:COLORADO STATE UNIVERSITY;REEL/FRAME:057538/0330 Effective date: 20190222 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20240121 |